Document:

License agreement

 Exhibit 10.3 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 LICENSE AGREEMENT 
  
 THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into as
of June 10, 2005 (the “Effective Date”) by and between EXELIXIS, INC., a Delaware corporation having its principal place of business at 170 Harbor Way, P.O. Box 511, South San
Francisco, California 94083 (“Exelixis”), and HELSINN HEALTHCARE S.A., a Swiss corporation having its principal place of business at via Pian Scairolo 9, 6912 Lugano, Switzerland
(“Helsinn”). Exelixis and Helsinn are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
  
 BACKGROUND 
  
 A. Exelixis is a biotechnology company that has expertise in the field of cancer and proprietary technology relating to Becatecarin. 
  
 B. Helsinn is a pharmaceutical company that has expertise in the
development and commercialization of pharmaceutical products. 
  
 C. Exelixis desires to grant to Helsinn, and Helsinn desires to receive, a license and other tangible assets to develop and commercialize Becatecarin based on the terms and conditions set forth below. 
  
 NOW THEREFORE, Exelixis
and Helsinn agree as follows: 
  

	1.	DEFINITIONS 

  
 Capitalized terms used in this Agreement (other than the headings of the Sections or Articles) shall have the following meaning set forth in this Article 1, or, if not
listed in this Article 1, the meaning as designated in the text of this Agreement. 
  
 1.1 “Affiliate” means, with respect to a particular Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For
the purposes of the definition in this Section 1.1, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or
indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.

  
 1.2 “Assumed Contracts” means the contracts
listed in Exhibit 1.2. 
  
 1.3
“Becatecarin” means: (i) the rebeccamycin analog compound known as Becatecarin (“XL119”), with CAS Identification No. CAS-119673-08-4 and CAS nomenclature 1,11-Dichloro-6-[ *
]-12,13-dihydro-12-(4-O-methyl-ß-D-glucopyranosyl)-5H-indolo[ * ]pyrrolo[ * ]carbazole-5,7(6H)-dione; and (ii) [ * ]. 
  

 1 

 1.4 “Control” or “Controlled” means, with respect to any
material, particular item of Information or intellectual property right, (i) that the Party owns and has the ability to grant to the other Party the license to such item provided for herein, without violating the terms of any agreement or other
arrangement with any Third Party, and/or (ii) that the Party has a license to such item and has the ability to grant to the other Party the license to such item provided for herein, without violating the terms of any agreement or other arrangement
with any Third Party. 
  
 1.5 “EU” means the
European Union, as its membership may be altered from time to time, and any successor thereto. The member countries of the European Union as of the Effective Date are Belgium, Denmark, Germany, Greece, Spain, France, Ireland, Italy, Luxemburg,
Netherlands, Austria, Portugal, Finland, Sweden, the United Kingdom, Estonia, Latvia, Lithuania, Poland, the Czech Republic, Slovakia, Hungary, Slovenia, Malta, and Cyprus. 
  
 1.6 “Exelixis Know-How” means all Information Controlled by Exelixis or its Affiliates as of the
Effective Date, including Information originated or developed by any Third Party, that relates to [ * ], including without limitation: (i) [ * ] any utilization or optimization thereof and related [ * ]; (ii) [ * ] data;
(iii) [ * ] data; (iv) [ * ] information; (v) [ * ]; (vi) [ * ] data; (vii) all [ * ]; and (viii) all [ * ] data. For sake of clarity, no trademarks or tradenames Controlled by Exelixis are included in
Exelixis Know-How. 
  
 1.7 “Exelixis Patent
Rights” means the Patents listed in Exhibit 1.7. 
  
 1.8 “FDA” means the United States Food and Drug Administration or any successor agency. 
  
 1.9 “Field” means any therapeutic use in humans or animals. 
  
 1.10 “Final Report” means the final report provided by Helsinn to Exelixis pursuant to Section 3.6 upon
completion of the first successful Phase 3 Clinical Trial for Becatecarin and describing in detail the data, analysis and conclusions of such clinical trial. As used in this Agreement, “successful” means, with respect to a Phase 3
Clinical Trial, [ * ]. 
  
 1.11 “First Commercial
Sale” means for each Product on a country-by-country basis, the first commercial sale in such country after regulatory approval of such Product in such country. A First Commercial Sale shall not include any Product sold for use in clinical
trials, for research or for other non-commercial uses, or that is supplied as part of a compassionate use or similar program. 
  
 1.12 “First Option” shall have the meaning set forth in Section 2.4.1. 
  
 1.13 “First Option Exercise Period” shall mean the period commencing on the Effective Date and ending on
the earlier of (a) ninety (90) days after Exelixis’ receipt of the Final Report, (b) Exelixis’ exercise of the First Option in accordance with Section 2.4.1, or (c) Exelixis’ written notification to Helsinn that it will not exercise
the First Option. 
  

 2 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 1.14 “First Option Negotiation Period” shall have the meaning set forth in Section
2.4.1. 
  
 1.15 “GAAP” means the United States
Generally Accepted Accounting Principles, consistently applied. 
  
 1.16 “Generic Product” means a pharmaceutical product that contains Becatecarin and [ * ]. 
  
 1.17 “IAS-IFRS” means an integrated system of International Accounting Standards and International Financial Reporting Standards,
consistently applied. 
  
 1.18 “IND” means
an Investigational New Drug application and any amendments thereto, as defined in the U.S. Food, Drug and Cosmetics Act and the regulations promulgated thereunder, or any corresponding or equivalent foreign application, registration or
certification. 
  
 1.19 “IND Transfer Date” shall
have the meaning set forth in Section 3.5. 
  
 1.20
“Information” means [ * ], including without limitation, [ * ]. 
  
 1.21 “Major Country” means any of the following countries, and their respective territories and possessions: United States, United
Kingdom, Germany, Italy, France, Spain and Japan. 
  
 1.22
“Market Exclusivity” shall be deemed to exist for a given Product in a given country [ * ]. 
  
 1.23 “Net Sales” means the gross amount invoiced or otherwise charged by Helsinn or its Affiliates or sublicensees for the sale of any
Product to any Third Party, less the following deductions (calculated in accordance with GAAP or IAS-IFRS, as applicable) to the extent actually incurred or allowed in connection with such sale of such Product: (i) reasonable and customary cash,
trade and quantity discounts; (ii) government-mandated rebates and/or charges; (iii) allowances for returned or rejected Product or retroactive price reductions; (iv) credits and/or allowances given or made for Indigent Patients Programs or similar
programs; (v) freight out (i.e., freight charges between the seller and the end user), handling fees and insurance, if invoiced to the purchaser; and (vi) sales, value-added (to the extent not otherwise refunded, credited or reimbursed) and other
direct taxes on the sale of Product (other than income taxes), if invoiced to the purchaser; (vii) [ * ]; and (viii) [ * ]. A Net Sale shall not include any Product sold for use in clinical trials, for research or for other
non-commercial uses, or that is supplied as part of a compassionate use or similar program. 
  
 1.24 “North American Territory” means: (i) the United States of America and its territories and possessions; and (ii) Canada and its provinces and territories. 
  
 1.25 “Option Field” means therapeutic use in the indications
of gall bladder cancer and bile duct cancer. 
  

 3 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 1.26 “Patents” means all: (i) United States patents, re-examinations, reissues,
renewals, extensions and term restorations, supplementary protection certificates, inventors’ certificates and foreign counterparts thereof; (ii) pending applications for United States patents, including provisional applications, continuations,
continuations-in-part, continued prosecution, divisional and substitute applications; and (iii) foreign counterparts of the foregoing. 
  
 1.27 “Phase 3 Clinical Trial” means a human clinical trial, the principal purpose of which is to establish efficacy and safety of a drug
in patients with the disease being studied as required in 21 C.F.R. §312.21(c) or similar clinical study in a country other than the United States for regulatory purposes 
  
 1.28 “Product” means: (i) Becatecarin; [ * ]. For clarity, Exelixis is granting Helsinn
rights under the Exelixis Know-How and Exelixis Patents solely to Becatecarin. Notwithstanding anything to the contrary, the license set forth in Section 2.1 does not grant Helsinn any rights under the Exelixis Know-How and Exelixis Patents to any
other compound or molecule Controlled by Exelixis. 
  
 1.29
“Regulatory Authority” means any governmental authority, including without limitation FDA or the European Medicines Agency (“EMEA”), with responsibility for granting any licenses or approvals necessary for the clinical
testing, marketing and sale of a Product in any country. 
  
 1.30 “ROFR” shall have the meaning set forth in Section 2.5. 
  
 1.31 “ROFR Field” means all therapeutic uses other than in the indications of gall bladder cancer or bile duct cancer. 
  
 1.32 “Second Option” shall have the meaning set forth in Section 2.4.2. 
  
 1.33 “Second Option Exercise Period” shall mean the
period commencing on the Effective Date and ending on the date ninety (90) days after Exelixis’ receipt of the Final Report. 
  
 1.34 “Second Option Negotiation Period” shall have the meaning set forth in Section 2.4.2. 
  
 1.35 “Successful First Interim Analysis” means that the
existing Phase 3 Clinical Trial for Becatecarin is not discontinued for futility upon completion of the first interim analysis performed when data are available for [ * ]. 
  
 1.36 “Third Party” means any person or entity other than Exelixis, Helsinn or an Affiliate of
Exelixis or Helsinn. 
  
 1.37 “Transition
Committee” shall have the meaning set forth in Section 3.1. 
  
 1.38 “Valid Claim” means: (i) any claim in an issued Patent in Exelixis Patent Rights that has not expired, been canceled, been declared invalid, or been admitted to be invalid or unenforceable
through reissue, disclaimer or otherwise; or (ii) a claim under a pending application for a Patent in Exelixis Patent Rights that has not been abandoned, canceled, 
  

 4 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 withdrawn from consideration, or finally determined to be unallowable in a decision from which no appeal can be taken.
For clarity, on a country-by-country basis, a Valid Claim shall include any patent claim that has been declared invalid (pending appeal) if and to the extent that such invalidity does not prejudice enforceability of the relevant Patent in accordance
with local laws of any such country. 
  

	2.	LICENSE AND OTHER RIGHTS 

  
 2.1 License to Helsinn. Subject to the terms and conditions of this
Agreement, Exelixis hereby grants to Helsinn and Helsinn hereby accepts a worldwide, exclusive, royalty-bearing license (with the unrestricted right to sublicense), under Exelixis Patent Rights and Exelixis Know-How, to make, have made, use,
develop, sell, offer for sale and import Products in the Field. For clarity, the Parties intend that the license in this Section 2.1 includes the ability to distribute, promote, and market Products. 
  
 2.2 Retained Rights. Pursuant to the License Agreement between
Exelixis and Bristol-Myers Squibb Company (“BMS”) dated July 17, 2001 (the “Upstream License”), Exelixis granted to BMS and its Affiliates a worldwide, non-exclusive, fully paid, royalty-free license, under Exelixis
Patent Rights and Exelixis Know-How, to make, have made, use, and test Becatecarin solely for internal pre-clinical research purposes: (i) to profile or test the activity of compounds other than Becatecarin; or (ii) to synthesize compounds that are
not Becatecarin. The exclusivity of Exelixis’ license to Helsinn in Section 2.1 is subject to such license to BMS. Exelixis retains the right to make, have made, import and have imported Becatecarin and Becatecarin for Injection (as such term
is defined at Section 3.4.3) to Helsinn in accordance with and for the sole purpose of Section 3.4.3. 
  
 2.3 Negative Covenants. Helsinn and its Affiliates shall not, and shall use commercially reasonable efforts to ensure that their sublicensees do
not, practice or sublicense Exelixis Patent Rights and/or Exelixis Know-How outside the scope of the license granted in Section 2.1. 
  
 2.4 Exelixis Option Rights. 
  
 2.4.1 First Option. Helsinn hereby grants Exelixis the exclusive option to obtain an exclusive license to distribute, promote, market, use, import,
offer for sale and/or sell Products in the North American Territory in the Option Field (the “First Option”). Upon the occurrence of any of the following triggering events: (i) Exelixis’ receipt of Helsinn’s written
solicitation to exercise the First Option; (ii) Helsinn’s receipt of Exelixis’ written request; or (iii) Helsinn’s providing Exelixis with the Final Report, Helsinn shall promptly provide to Exelixis under confidentiality such
information and data that may be relevant to Exelixis’ evaluation of whether it wishes to acquire such a license and that Helsinn usually discloses to potential partners licensees and distributors. Exelixis may exercise the First Option by
written notification to Helsinn at any time during the First Option Exercise Period. Commencing upon Helsinn’s receipt of such notification or upon Exelixis’ receipt of Helsinn’s written solicitation to Exelixis to exercise the First
Option, the Parties shall negotiate on an exclusive basis in good faith for [ * ] days (the “First Option Negotiation Period”) to reach agreement on the commercially reasonable terms and conditions of an agreement for the
distribution, promotion, marketing, use, 
  

 5 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 importation, offer for sale and/or sale of Products by Exelixis in the North American Territory in the Option Field. If
Exelixis fails to exercise the First Option during the First Option Exercise Period, or if the Parties fail to execute an agreement within the First Option Negotiation Period or any mutually agreed extension thereof, then Helsinn shall be free
thereafter to directly distribute, promote, market, use, import and sell the Products in the North American Territory and/or, subject to Section 2.4.2, to discuss, negotiate and enter into an agreement with a Third Party for the distribution,
promotion, marketing, use, importation, offer for sale and/or sale of Products in the North American Territory in the Option Field. If the Parties enter into an agreement for the license described in this Section 2.4.1, the Parties acknowledge and
agree that Exelixis shall not [ * ] but, with Helsinn’s prior written consent (which shall not be unreasonably withheld or delayed), Exelixis may [ * ]. 
  
 2.4.2 Second Option. In the event that, during the Second Option Exercise Period, Helsinn and any Third Party agree
on the financial terms under which such Third Party would have the opportunity to obtain a license to distribute, promote, market, use, import, offer for sale and/or sell Products in the North American Territory in the Option Field, then, prior to
entering into a legally binding agreement with such Third Party, Helsinn shall immediately: (i) notify Exelixis in writing of the financial terms agreed upon with such Third Party; (ii) provide Exelixis with all information provided to such Third
Party with respect to the Products; and (iii) provide Exelixis with the opportunity to match such Third Party’s offer within [ * ] days of Exelixis’ receipt of such notification and information (the “Second Option”)
and the Parties shall proceed as follows: 
  
 (a) If
Exelixis notifies Helsinn in writing during such [ * ] day period that it will match such Third Party’s offer and will agree to the marketing commitments set forth in Section 2.4.3, then Helsinn may provide such Third Party with one (1)
opportunity to increase its offer in writing in the [ * ] days following Helsinn’s receipt of Exelixis’ notice and the Parties shall proceed as follows: 
  
 (1) If such Third Party either (A) increases its offer, whereby Helsinn shall so notify Exelixis in writing and
provide Exelixis the opportunity to match such Third Party’s final offer within [ * ] days of Exelixis’ receipt of such notification from Helsinn, and if Exelixis agrees in writing to match such Third Party’s final offer, or
(B) does not increase its offer within [ * ] days of Helsinn’s receipt of notification from Exelixis matching such Third Party’s initial offer, then the Parties shall negotiate on an exclusive basis in good faith for [ * ]
days (the “Second Option Negotiation Period”) to reach agreement on the other commercially reasonable terms and conditions of an agreement for the distribution, promotion, marketing, use, importation, offer for sale and/or sale of
such Product by Exelixis in the North American Territory in the Option Field. In the event that the Parties negotiate in good faith during the Second Option Negotiation Period but fail to execute an agreement during such period, then Helsinn shall
be free thereafter to fully exploit the Products in the North American Territory in the Option Field directly and/or through any Third Party; or 
  
 (2) If such Third Party increases its offer, whereby Helsinn shall so notify Exelixis in writing and provide Exelixis the opportunity to match
such Third Party’s final offer within [ * ] days of Exelixis’ receipt of such notification from Helsinn, and if Exelixis does not agree in writing to match such Third Party’s final offer, Helsinn shall be free thereafter to
fully exploit the Products in the North American Territory in the Option Field directly and/or through any Third Party. 
  

 6 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) If Exelixis fails to notify Helsinn in writing during such [ * ] day period that it
will match such Third Party’s offer, then Helsinn shall be free thereafter to fully exploit the Products in the North American Territory in the Option Field directly and/or through any Third Party. 
  
 If the Parties enter into an agreement for a license pursuant to the Second
Option, Exelixis shall not [ * ] but, with Helsinn’s prior written consent (which shall not be unreasonably withheld or delayed), Exelixis may [ * ]. 
  
 2.4.3 Marketing Commitments. In the event Exelixis enters into a license agreement with Helsinn pursuant to
Exelixis’ exercise of either the First Option or the Second Option, such license agreement will include: (i) a [ * ] marketing commitment in the United States of [ * ] as mutually agreed in good faith by the Parties [ * ];
(ii) a [ * ] amount of [ * ], as suggested by [ * ] or as mutually agreed in good faith in writing by the Parties [ * ]; (iii) [ * ], as mutually agreed in good faith by the Parties; and (iv) a [ * ], as
mutually agreed in good faith by the Parties. 
  
 2.5 Exelixis
Right of First Refusal. Prior to offering any Third Party the opportunity to obtain a license to distribute, promote, market, use, import, offer for sale and/or sell any Product in the North American Territory in the ROFR Field, and [ *
], Helsinn shall provide Exelixis with the opportunity to consider whether it wishes to acquire such a license (the “ROFR”). Helsinn shall promptly provide to Exelixis under confidentiality such information and data that may be
relevant to Exelixis’ evaluation of whether it wishes to acquire such a license and that Helsinn usually discloses to potential partners licensees and distributors. Exelixis shall have [ * ] days following receipt of such information in
which to inform Helsinn in writing that Exelixis is interested in exercising the ROFR and acquiring such a license. If Exelixis notifies Helsinn of its interest, the Parties shall negotiate in good faith on an exclusive basis for [ * ] days
to reach agreement on the commercially reasonable terms and conditions of an agreement for the distribution, promotion, marketing, use, importation, offer for sale and/or sale of such Product by Exelixis in the North American Territory in the ROFR
Field. If Exelixis fails to notify Helsinn of its interest during the [ * ] day period, or if the Parties fail to execute an agreement within the [ * ] day period, then Helsinn shall be free to pursue an agreement with a Third Party
for the distribution, promotion, marketing and/or sale of such Product in the North American Territory in the ROFR Field (or to directly distribute, promote, market, use, import and sell such Products in the North American Territory in the ROFR
Field). If the Parties enter into an agreement for the license described in this Section 2.5, the Parties acknowledge and agree that Exelixis shall not [ * ] but, with Helsinn’s prior written consent (which shall not be unreasonably
withheld or delayed), Exelixis may [ * ]. 
  
 2.6 No
additional Licenses. Except for the express license granted in this Article 2, neither Party shall be granted any license (either express, implied or by estoppel) to the Patents or Information Controlled by the other Party. 
  

 7 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 2.7 IND Transfer. Exelixis hereby agrees to transfer and assign to Helsinn, in accordance with the
procedures set forth in Section 3.5, and Helsinn hereby agrees to receive from Exelixis in accordance with such procedures, all of Exelixis’ right, title and interest to Exelixis’ IND No. 66588 for Becatecarin in the United States. Helsinn
understands and acknowledges that, with respect to certain Becatecarin clinical trials being conducted in countries outside the United States, Exelixis is the Sponsor of Record, and Exelixis is not the holder of the applicable INDs in such countries
because Exelixis does not have a sufficient presence in those countries. Accordingly, Exelixis’ Third Party contractor holds the IND(s) for Becatecarin for those countries. Such IND(s) are listed on Exhibit 2.7, and, prior to the IND
Transfer Date (defined in Section 3.5), Exelixis will transfer its rights in such INDs to Helsinn so that Helsinn shall be the Sponsor of Record and/or IND holder, as applicable for such INDs. 
  
 2.8 Nonproprietary Name and Trademark Rights. The Parties acknowledge
and agree that Becatecarin is a United States Accepted Name (“USAN”) and International Nonproprietary Name (“INN”). Exelixis hereby assigns to Helsinn all right, title and interest in any rights owned by Exelixis
with respect to the name “Becatecarin”. No other right (either express, implied or by estoppel) is granted by this Agreement to Helsinn to use in any manner any other name associated with Exelixis or any trademark or tradename Controlled
by Exelixis. Helsinn shall be free to use whatever trademark or trademarks it will deem appropriate in connection with the Products, including Becatecarin, except for any other name associated with Exelixis or any trademark or tradename Controlled
by Exelixis. 
  

	3.	TRANSITION COMMITTEE; TRANSFER OF KNOW-HOW AND ASSUMED
CONTRACTS; OTHER OBLIGATIONS 

  
 3.1 Transition Committee. Within [ * ] days of the Effective Date, the Parties shall form a committee to facilitate the transfer to Helsinn
of Information in Exelixis’ possession and Control that relates to Becatecarin and/or to the Products in accordance with the terms of this Agreement and to assist Helsinn in identifying and addressing any issues associated with such transfer
(the “Transition Committee”). In addition to its primary goals of facilitating a smooth transfer of Becatecarin-related Information from Exelixis to Helsinn to allow Helsinn to exercise its rights under this Agreement and providing
a forum to discuss and coordinate the Parties’ transition activities, the Transition Committee shall perform those functions which will be deemed appropriate or advisable by the Parties, in accordance with the working procedures agreed to in
writing by the Parties. Each Party shall designate two (2) representatives to serve as its members of the Transition Committee. Either Party may designate a temporary substitute for each of its representatives that is unable to be present at or
otherwise participate in a particular meeting. Either Party may replace its representatives from time to time by written notice to the other Party specifying the representative(s) to be replaced and the replacement therefor. 
  
 3.1.1 Limited Authority. The role of the Transition Committee shall be
advisory in nature, with the goal of serving as a forum for the sharing of information and facilitating communications between the Parties. The Transition Committee shall not have any power to amend, modify or waive compliance with, this Agreement.

  

 8 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 3.1.2 Meetings. The Transition Committee shall meet at such times as it elects to do so. Meetings
may be held in person or by audio or video teleconference. Each Party shall be responsible for all of its own expenses for participating in the Transition Committee. 
  
 3.1.3. Dissolution of the Transition Committee. The Transition Committee shall dissolve on the date [ * ]
months after the Effective Date, unless the Parties mutually agree in writing to extend such period. 
  
 3.2 Transfer of Exelixis Know-How. Within [ * ] of the Effective Date, Exelixis shall commence the disclosure and transfer to Helsinn of all
Exelixis Know-How. Exelixis shall use commercially reasonable efforts to complete such disclosure and transfer [ * ]. The Parties agree and acknowledge that Exelixis may retain one or more copies of any Exelixis Know-How and may use such
Exelixis Know-How for archival purposes and for the purpose of the manufacture and supply of Becatecarin and Becatecarin for Injection pursuant to Section 3.4.3. Exelixis shall not be required to provide any on-site advice or support in connection
with this Section 3.2. [ * ] shall bear its own expenses in connection with this Section 3.2, except that Helsinn shall reimburse Exelixis for reasonable travel expenses incurred by Exelixis to attend, at Helsinn’s request and with
Exelixis’ consent, any meetings not held at an Exelixis facility. 
  
 3.2.1. Further disclosure of relevant Information. Exelixis shall use commercially reasonable efforts to [ * ] disclose and transfer to Helsinn any further Information related to Becatecarin and/or to the Products which [ *
]. 
  
 3.3 Transfer of Assumed Contracts. 

 
 3.3.1 Assignment. Subject to the terms and conditions of this
Agreement and to any necessary consent by Third Parties, Exelixis sells, transfers and assigns the Assumed Contracts to Helsinn effective upon the later of the Effective Date and the date upon which the Third Party consents to such transfer.

  
 3.3.2 Assumption of Liability. Subject to the terms and
conditions of this Agreement and to any necessary consent by Third Parties, Helsinn assumes all obligations, duties and liabilities of Exelixis that are related to the Assumed Contracts and that arise on and after: (a) the Effective Date (with
respect to each Assumed Contract for which a Third Party’s consent is not necessary for assigning such Assumed Contract); and (b) the date upon which the relevant Third Party consents to the assignment of a given Assumed Contract (with respect
to each Assumed Contract for which a Third Party’s consent is necessary for assigning such Assumed Contract). Notwithstanding the foregoing, Helsinn shall not be responsible for any liability under an Assumed Contract to the extent attributable
to a breach by Exelixis of its obligations under the Assumed Contracts accrued prior to the effective date of assignment. Such assumed obligations, duties and liabilities shall include but are not limited to, payment obligations to existing clinical
study sites and providers of storage and distribution services with respect to Becatecarin. Exelixis shall retain all liability for its failure to fulfill any obligations, including but not limited to payment obligations, under each Assumed Contract
that accrued prior to the effective date of assignment to Helsinn of said Assumed Contract. 
  

 9 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 3.3.3 Consents. Notwithstanding anything in this Agreement to the contrary, this Agreement
shall not constitute an agreement to assign any Assumed Contract or any claim or right or any benefit arising thereunder or resulting therefrom if an attempted assignment thereof, without the consent of a Third Party, would constitute a breach or
other contravention thereof or in any way adversely affecting the rights of Exelixis or Helsinn. Exelixis will use commercially reasonable efforts (but without any payment of money or other consideration by Exelixis) to obtain the consent of any
such Third Party to any such Assumed Contract for the assignment thereof to Helsinn as Helsinn may reasonably request. If any such consent is not obtained, or if an attempted assignment of any such Assumed Contract would be ineffective or would
adversely affect the rights of Exelixis thereunder so that Helsinn would not in fact receive all such rights, the Parties will cooperate in a mutually agreeable arrangement under which Helsinn would obtain the benefits and assume the obligations
thereunder in accordance with this Agreement and as reasonably permitted under the terms of such Assumed Contract at no cost to Helsinn in excess of the cost Helsinn would have incurred (without modification to the terms of such Assumed Contract) if
the consent had been obtained, including sub-contracting or sub-licensing to Helsinn, to the extent practicable depending upon the nature of the Assumed Contract. 
  
 3.4 Product Supply. 
  
 3.4.1 Generally. As between the Parties and subject to Section 3.4.2 and Section 3.4.3 below, Helsinn shall be solely responsible for manufacturing
and supplying, either directly or indirectly, all supplies of Product for clinical, commercial and other purposes. In the event that Exelixis obtains, pursuant to Section 2.4 or 2.5, the right to distribute, promote, market and/or sell Products in
the North American Territory, Exelixis shall obtain its supply of Products for such purposes [ * ] from Helsinn at a price [ * ]. 
  
 3.4.2 Product Inventory. Exelixis shall transfer to Helsinn all of Exelixis’ right, title and interest in all clinical supplies of Product in
Exelixis’ possession [ * ]. Exelixis shall deliver such clinical supplies in its possession to Helsinn [ * ] Exelixis’ storage facility together with [ * ]. If requested by Helsinn in writing, Exelixis shall arrange
for transportation and insurance of such clinical supplies at Helsinn’s expense. 
  
 3.4.3 Supply of Product for the Existing Phase 3 Clinical Trial. 
  
 (a) Exelixis shall supply to Helsinn by 30 April 2006 [ * ] of Becatecarin (“Becatecarin for Injection”) for the Phase 3
Clinical Trial of the Product that is on-going as of the Effective Date. Such Becatecarin for Injection will [ * ] as the Product being used in such on-going Phase 3 Clinical Trial. For clarity, Exelixis may enter into agreements with Third
Parties as necessary or useful to indirectly manufacture and supply such Becatecarin and Becatecarin for Injection. Such manufacture and supply shall be in accordance with applicable regulatory laws. The price per vial which will be charged by
Exelixis to Helsinn shall be [ * ]. Helsinn shall pay Exelixis within [ * ] days of receiving the relevant invoice for the [ * ] Becatecarin for Injection, which shall specify the details of [ * ]. 
  

 10 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) Exelixis shall be responsible for preparing the documentation of analytical methods and
validation procedures related to the manufacture of Becatecarin and Becatecarin for Injection (the “CMC Documentation”). Exelixis shall prepare such CMC Documentation in accordance with applicable regulations and shall provide
Helsinn with the completed CMC Documentation, along with the [ * ]. 
  
 (c) Exelixis shall also notify Helsinn in writing of the scheduled date for completing the fill and finish of the Becatecarin for Injection. Within [ * ] weeks of receiving such notice, Helsinn shall
designate to Exelixis in writing the cGMP-qualified storage facility (suitable for storage of the completed Becatecarin for Injection) that Helsinn desires Exelixis to ship such completed Becatecarin for Injection. If Exelixis does not receive any
designation from Helsinn by the end of such [ * ] week period, then Exelixis shall ship such completed Becatecarin for Injection to its designated storage facility [ * ], where it will be stored [ * ] until Helsinn requests in
writing that such Becatecarin for Injection be distributed to the applicable storage facility for use in the on-going Phase 3 Clinical Trial for the Product. Exelixis shall transfer to Helsinn all of Exelixis’ right, title and interest in such
Becatecarin for Injection on the later of: (i) [ * ]; or (ii) the date such [ * ]. 
  
 3.5 Transfer of IND. On a date mutually agreed by the Parties in writing, but no later than [ * ]; provided, however, that the
Parties may mutually agree to extend such date if Exelixis has not transferred to Helsinn [ * ] with respect Exelixis’ IND No. 66588 by [ * ] period (the “IND Transfer Date”), Exelixis shall notify the applicable
Regulatory Authorities in writing that it is transferring Exelixis’ IND No. 66588 for Becatecarin to Helsinn pursuant to Section 2.7, and Helsinn shall notify the applicable Regulatory Authorities in writing that it is accepting such IND and
all responsibilities associated therewith, including without limitation, the responsibility for reporting adverse events. If Helsinn does not satisfy the applicable Regulatory Authorities’ requirements for holding an IND, then Helsinn shall
either: (i) engage an entity that satisfies such requirements to accept such IND and its associated responsibilities on behalf of Helsinn; or (ii) enter into a contractual relationship with one or more entities for the provision of services such
that Helsinn is able to satisfy such Regulatory Authorities’ requirements. Helsinn shall identify any such entity(ies) and provide documentation of its satisfaction of the relevant Regulatory Authority requirements to Exelixis at least [ *
] days prior to the IND Transfer Date. If Helsinn fails to do so, then Exelixis may, at Helsinn’s expense, make whatever arrangements it believes are appropriate to ensure the full and complete transfer of the IND to Becatecarin to Helsinn
or Helsinn’s agent on the IND Transfer Date.  
  
 3.5.1 During the period from the Effective Date until the IND Transfer Date, Helsinn shall reimburse Exelixis for all of Exelixis’ direct and indirect costs of maintaining the existing Phase 3 Clinical Trial for Becatecarin
during such period (the “Interim Trial Costs”). These indirect costs shall be [ * ] per year. On a monthly basis, Exelixis shall invoice Helsinn for the Interim Trial Costs for the preceding month and shall send to Helsinn
appropriate documentation evidencing such costs, and Helsinn shall pay Exelixis the amount of such Interim Trial Costs within [ * ] days of receiving each such invoice. The Interim Trial Costs payments made by Helsinn shall be nonrefundable
and noncreditable.  
  
 3.6 Diligence. Helsinn shall
use commercially reasonable efforts to develop, obtain Regulatory Approval for, and commercialize the Product in each Major Country. Such efforts 
  

 11 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 shall be no less than those efforts a pharmaceutical company of the size of Helsinn would make with respect to a
pharmaceutical product of comparable commercial potential, stage of development, and medical/scientific, technical and regulatory profile. In particular, Helsinn shall use commercially reasonable efforts to complete the existing, and any subsequent,
Phase 3 Clinical Trial for Becatecarin, including analysis of all case report forms and other clinical data and investigator observations, and shall promptly provide Exelixis with the Final Report. 
  
 3.7 Regulatory and CMC Responsibilities. 
  
 3.7.1 IND. [ * ] prior to the IND Transfer Date, Exelixis
shall be responsible for continuing all activities (including clinical development activities) conducted under the INDs for Becatecarin, provided however that any and all [ * ] shall have to be previously approved and authorized in writing by
Helsinn. Commencing on the IND Transfer Date, Helsinn shall be responsible for maintaining the active status of the INDs for Becatecarin and for performing all obligations associated with such INDs. 
  
 3.7.2 Regulatory and Medical Communication. Beginning on the IND
Transfer Date, Helsinn and/or its agents shall assume all responsibility for all correspondence and communication relating to the Product with Regulatory Authorities, and the physicians and other health care professionals. Helsinn shall keep such
records and make such reports as shall be reasonably necessary to document communications to Regulatory Authorities and to physicians in compliance with all applicable regulatory requirements. After the IND Transfer Date, Exelixis shall refer any
questions relating to the Product raised by Regulatory Authorities and health care professionals to Helsinn for its follow-up 
  
 3.7.3 Adverse Event Reporting. After the IND Transfer Date, Helsinn shall be responsible for the adverse experience and safety reporting for the
Product in compliance with the requirements of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 321 et seq. and the regulations promulgated thereunder and the equivalent regulations in other countries in the world. Exelixis shall provide
interim adverse experience and safety reporting services on Helsinn’s behalf between the Effective Date and the IND Transfer Date. 
  
 3.8 Additional Assistance. Upon the Effective Date and [ * ], Exelixis shall provide to Helsinn, at Helsinn’s written request, a
commercially reasonable amount of consulting assistance on [ * ] issues related to Becatecarin, including [ * ]. Exelixis shall also, at reasonable times during normal business hours, provide Helsinn and its representatives an
opportunity to meet at Exelixis’ facilities with certain Exelixis employees who have material knowledge pertaining to Becatecarin-related contracts, data and records. Exelixis shall also use commercially reasonable efforts to [ * ].

  
 3.9 Exchange of Information. Helsinn shall provide
Exelixis twice a year with written reports on the progress of Helsinn’s efforts to develop and commercialize Products. Additionally, Helsinn shall provide Exelixis with a detailed annual written report summarizing 
  

 12 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 the Helsinn’s progress at developing and commercializing Products, and any other information reasonably requested by
Exelixis and which may have a material impact on Exelixis’ rights or obligations under this Agreement.  
  
 3.10 Compliance with Laws. Helsinn shall perform, and shall use commercially reasonable efforts to ensure that its Affiliates, sublicensees and
Third Party contractors perform, all development and commercialization activities for which it is responsible under this Agreement in good scientific and medical manner and in compliance with all applicable laws, rules and regulations. 

 

	4.	FINANCIAL TERMS 

  
 4.1 Up-front Payment. Upon execution of this Agreement, Helsinn shall pay Exelixis an up-front fee of four million dollars ($4,000,000). Such
up-front fee shall be nonrefundable and noncreditable and shall be paid by Helsinn within [ * ] days of receipt of the relevant invoice from Exelixis. The Parties acknowledge and agree that such up-front fee includes payment by Helsinn for
the Product inventory in Exelixis’ possession as of the Effective Date to be transferred to Helsinn in accordance with Section 3.4.2. 
  
 4.2 Milestone Payments. In partial consideration for the grant of the license to Helsinn in Section 2.1, Helsinn shall pay Exelixis the amounts set
forth below upon the first occurrence of the events described below for any Product. Helsinn shall notify Exelixis in writing within [ * ] days of the achievement of each such event. All milestone payments shall be nonrefundable and
noncreditable and shall be paid by Helsinn within [ * ] days of receipt of the relevant invoice from Exelixis. 
  

			
	 Milestone Events

	  	 Amounts

	 [ * ]

	  	[ * ]
	 	  	

	 [ * ]
  

	  	 [ * ]
  

	 [ * ]
  

	  	 [ * ]
  
  

	 	  	

	 [ * ]

	  	 [ * ]
  

	 [ * ]

	  	 [ * ]
  

  
 If any milestone event (the
“Later Milestone”) is achieved prior to the achievement of a milestone event listed above it in the foregoing table (an “Earlier Milestone”), then Helsinn shall pay to Exelixis within [ * ] days of the
achievement of such Later Milestone, the amount for such Later Milestone plus the amount for each and every Earlier Milestone not yet achieved. Notwithstanding the foregoing, the [ * ] milestone event shall not be considered an Earlier
Milestone with respect to the [ * ] milestone event. 
  

 13 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 4.3 Royalties. 
  
 4.3.1 Products [ * ]. For Products that are [ * ], Helsinn shall, subject to Section 6.3, pay Exelixis
royalties equal to: 
  
 (a) Until the worldwide,
aggregate, annual Net Sales of all Products exceeds [ * ], [ * ] of the Net Sales of such Products; and 
  
 (b) Once the worldwide, aggregate, annual Net Sales of all Products exceeds [ * ], [ * ] of the Net Sales of such Products.

  
 Helsinn’s obligation to pay royalties pursuant to this Section 4.3.1
shall last, on a Product-by-Product and country by country basis, until the later to expire of: (i) [ * ]; or (ii) [ * ] for the Product in such country (provided that [ * ] for a given Product in a given country shall not
extend beyond [ * ] after the First Commercial Sale of such Product in such country). 
  
 4.3.2 Products Not [ * ]. Subject to Section 4.3.3, for Products that are not, or are no longer, [ * ], Helsinn shall pay Exelixis royalties equal to: 
  
 (a) Until the worldwide, aggregate, annual Net Sales of all Products
exceeds [ * ], [ * ] of the Net Sales of such Products; and 
  
 (b) Once the worldwide, aggregate, annual Net Sales of all Products exceeds [ * ], [ * ] of the Net Sales of such Products. 
  
 Helsinn’s obligation to pay royalties pursuant to this Section 4.3.2 shall expire, on a Product-by-Product and country-by-country
basis, on the [ * ]. 
  
 4.3.3 Generic Competition.
If a Third Party [ * ] a Generic Product in a particular country, and Helsinn can demonstrate by competent evidence that the number of units sold in such country by such Third Party in any calendar year exceeds [ * ] of the total
number of units of Product sold by Helsinn, its Affiliates or sublicensees in such country during such year, then Helsinn [ * ] during said calendar year. 
  
 4.4 Reports. Within [ * ] days after the end of the calendar quarter in which the First Commercial Sale in any
country occurs, and on each calendar quarter thereafter, Helsinn shall send to Exelixis (i) a payment of all royalties owed to Exelixis for such calendar quarter; and (ii) a report of Net Sales of Products in sufficient detail on a
country-by-country basis to permit confirmation of the accuracy of the royalty payment made, including the number of Products sold, the gross sales and Net Sales of Products, the royalties payable (in dollars), the method used to calculate the
royalty, and the exchange rates used. 
  
 4.5 Payments. All
references to “dollars” or “$” means the legal currency of the United States. All amounts due to Exelixis by Helsinn under this Agreement shall be paid in dollars by wire transfer in immediately available funds to
an account designated by Exelixis. If 
  

 14 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 any currency conversion shall be required in connection with any payment or accounting of costs and expenses under this
Agreement (including, without limitation, for the purpose of calculating the amount of worldwide, aggregate, annual Net Sales as mentioned at Sections 4.3.1 and 4.3.2), such conversion shall be made by using the average of the exchange rates for the
purchase of dollars as published in The Wall Street Journal, Western Edition, or a comparable publication, on the last business day of each of the three (3) months of the calendar quarter for which the payment is made. If Helsinn is prevented
from paying Exelixis any royalties in a given country because the local currency is blocked and cannot be removed from the country, then Helsinn shall promptly pay Exelixis in the local currency by deposit in a local bank designated by Exelixis, to
the extent permitted by local law. 
  
 4.6 Withholding of
Taxes. Helsinn may withhold from payments due to Exelixis amounts for payment of any withholding tax that is required by law to be paid to any taxing authority with respect to such payments. Helsinn shall provide to Exelixis all relevant
documents and correspondence, and shall also provide to Exelixis any other cooperation or assistance on a reasonable basis as may be necessary to enable Exelixis to claim exemption from such withholding taxes and to receive a full refund of such
withholding tax or claim a foreign tax credit. Helsinn shall give proper evidence from time to time as to the payment of such tax. Helsinn may treat Exelixis as a US resident person if it has provided a valid Form W-9 or equivalent or a signed
statement concerning its permanent residence address and Taxpayer Identification Number (“TIN”). 
  
 4.7 Late Payments. Any amounts not paid by Helsinn when due under this Agreement shall be subject to interest from and including the date payment
is due through and including the date upon which Exelixis has received payment at a rate equal to [ * ] calculated daily on the basis of a 365-day year, or similar reputable data source, or, if lower, the highest rate permitted under
applicable law. 
  
 4.8 Records and Audit. During the term
of this Agreement and for a period of [ * ] years thereafter, Helsinn shall keep complete and accurate records pertaining to the development, manufacture, use, sale or other disposition of the Products, in sufficient detail to permit Exelixis
to confirm the accuracy of all payments due hereunder and compliance with the diligence obligations set forth in Section 3.6. Exelixis shall have the right to cause an independent, certified public accountant reasonably acceptable to Helsinn, to
audit such records to confirm the accuracy of Helsinn’s payments; provided, however, that such auditor shall not disclose Helsinn’s confidential information to Exelixis, except to the extent such disclosure is necessary to verify the
payments due under this Agreement. Exelixis shall bear the full cost of such audit unless such audit discloses an underpayment of more than [ * ] from the amounts previously paid for the audited period. In such case, Helsinn shall bear the
full cost of such audit. Helsinn shall remit any underpayment identified by such audit (plus applicable interest) to Exelixis within thirty (30) days of the results of such audit. Reciprocally, if the audit discloses an overpayment from the amount
of royalties previously paid by Helsinn, Exelixis shall remit any such overpaid amount (plus applicable interest) to Helsinn within thirty (30) days of the results of such audit. The terms of this Section 4.8 shall survive any termination or
expiration of this Agreement for a period of [ * ]. 
  

 15 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	5.	CONFIDENTIALITY 

  
 5.1 Nondisclosure of Confidential Information. For all purposes hereunder, “Confidential Information” shall mean all Information
disclosed by one Party to the other Party pursuant to this Agreement. During the term of this Agreement and for a period of [ * ] years thereafter, a Party receiving such item of Confidential Information of the other Party will (i) maintain
in confidence such item of Confidential Information and not disclose such item of Confidential Information to any Third Party without prior written consent of the other Party, except for disclosures made in confidence to any Third Party under terms
consistent with this Agreement and made in furtherance of this Agreement or of rights granted to a Party hereunder, and (ii) not use the other Party’s Confidential Information for any purpose except those permitted by this Agreement.

  
 5.2 Exceptions. The obligations in Section 5.1 shall
not apply with respect to any portion of the Confidential Information that the receiving Party can show by competent written proof: 
  
 (a) Is publicly disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party hereunder; 
  
 (b) Was known to the receiving Party or any of its Affiliates,
without obligation to keep it confidential, prior to disclosure by the disclosing Party; 
  
 (c) Is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without obligation to keep it confidential; 
  
 (d) Is published by a Third Party or otherwise becomes publicly
available or enters the public domain, either before or after it is disclosed to the receiving Party; or 
  
 (e) Has been independently developed by employees or contractors of the receiving Party or any of its Affiliates without the aid, application or
use of Confidential Information of the disclosing Party. 
  
 5.3 Authorized Disclosure. Each Party may disclose the Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
  
 (a) Filing or prosecuting patents relating to Products; 

 
 (b) Regulatory filings; 
  
 (c) Prosecuting or defending litigation; 
  
 (d) Complying with applicable governmental regulations; and

  
 (e) Disclosure, in connection with the performance of
this Agreement, to Affiliates, sublicensees, research collaborators, employees, consultants, or agents, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent in scope to those set
forth in this Article 5. 
  

 16 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties.
Such terms may be disclosed by a Party to investment bankers, investors, and potential investors (and by Helsinn to potential sub-licensees and distributors), each of whom prior to disclosure must be bound by obligations of confidentiality and
non-use at least equivalent in scope to those set forth in this Article 5. In addition, a copy of this Agreement may be filed, furnished or submitted to the Securities and Exchange Commission by Exelixis. In connection with any such filing, Exelixis
shall endeavor to obtain confidential treatment of economic and trade secret information and shall deliver to Helsinn in advance of any filing a redacted copy of this Agreement to enable Helsinn to give comments and suggestions on economic and trade
secret information to be kept confidential. 
  
 In any event, the Parties agree to
take all reasonable action to avoid disclosure of Confidential Information except as permitted hereunder. 
  
 5.4 Press Releases. Each Party shall be entitled to issue a press release, as approved by both Parties and attached hereto as Exhibit 5.4,
upon the execution of this Agreement. If either Party desires to make any subsequent public announcement (e.g. press release) concerning the terms of this Agreement or the activities hereunder, such Party shall give reasonable advance notice of the
proposed text of such announcement to the other Party for its review and approval prior to announcement, such approval shall not be unreasonably delayed or withheld. Such other Party shall provide its comments, if any, within [ * ] days after
receipt of the proposed text and the Party making such announcement shall consider and address all such comments in good faith. Notwithstanding anything to the contrary, such approval shall not be needed if such public announcement: (i) is required
pursuant to the disclosure requirements of the U.S. Securities and Exchange Commission or the national securities exchange or other stock market on which such Party’s securities are traded, provided however that in this case the proposed text
of the announcement shall, unless impracticable, be disclosed in advance to the other Party for information and comments; or (ii) solely discloses information that has previously been approved for disclosure by the other Party. 
  

	6.	INTELLECTUAL PROPERTY 

  
 6.1 Ownership of Inventions. Each Party shall own any inventions made solely by its employees, agents or independent contractors in their
activities hereunder. Inventions hereunder made jointly by employees, agents or independent contractors of each Party in the course of performing under this Agreement shall be owned jointly by the Parties in accordance with the joint ownership
interests of co-inventors under U.S. patent laws. Inventorship shall be determined in accordance with U.S. patent laws. 
  
 6.2 Patent Prosecution, Maintenance and Enforcement. 
  
 6.2.1 Patent Prosecution and Maintenance. Exelixis and/or BMS will prosecute and maintain the Exelixis Patent Rights, including conducting any
interferences, 
  

 17 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Exelixis shall provide
Helsinn with a revised Exhibit 1.7 updating the status of the Exelixis Patent Rights on an annual basis or more frequently if requested by Helsinn (but in no event more than quarterly). 
  
 6.2.2 Enforcement of Patent Rights by Exelixis. If either Party becomes aware of a suspected infringement of Exelixis
Patent Rights in the Field, such Party shall notify the other Party promptly, and following such notification, the Parties shall confer. Exelixis shall have the first right, but shall not be obligated, to take any actions or bring any proceedings
regarding the infringement at its own expense, in its own name, and entirely under its own direction and control. Helsinn will reasonably assist Exelixis (at Exelixis’ expense) in such actions or proceedings if so requested, and will lend its
name to such actions or proceedings if required by law. Helsinn shall have the right to participate and be represented in any such proceeding by its own counsel at its own expense, in which case [ * ]. No settlement of any such action or
proceeding that restricts the scope or affects the enforceability of Exelixis Patent Rights may be entered into by Exelixis without the prior consent of Helsinn, which consent shall not be unreasonably withheld. 
  
 6.2.3 Enforcement of Patent Rights by Helsinn. If Exelixis fails to
take any action or bring any proceeding regarding infringement pursuant to Section 6.2.2 within [ * ] days of the provision or receipt of notice of suspected infringement, then Helsinn may take such action or bring such proceeding at its own
expense, in its own name, and entirely under its own direction and control. Exelixis will reasonably assist Helsinn (at Helsinn’s expense) in any action or proceeding being prosecuted or defended by Helsinn, if so requested by Helsinn or
required by law in order for Helsinn to bring such action, including but not limited to executing any necessary documents such as any necessary power of attorney and including, if required, being joined as a necessary party. Exelixis shall have the
right to participate and be represented in any such proceeding by its own counsel at its own expense, [ * ]. No settlement of any such action or proceeding that restricts the scope or affects the enforceability of Exelixis Patent Rights may
be entered into by Helsinn without the prior consent of Exelixis, which consent shall not be unreasonably withheld. It is however understood that, irrespective of Helsinn’s decision to sue or not to sue the infringer, as well as irrespective of
the outcome of the proceedings, [ * ]. 
  
 6.3 Third
Party Infringement Claims. If an allegation is made or claim is brought by a Third Party that any activity related to a Product infringes the intellectual property rights of such Third Party, each Party will give prompt written notice to the
other Party of such claim. The Parties shall fully cooperate to defend against such allegation or claim, each bearing its own expenses. Neither Party shall enter into any settlement of any claim described in this Section 6.3 that affects the other
Party’s rights or interests without such other Party’s written consent, which consent shall not be unreasonably withheld or delayed. If a Party is entitled to indemnification pursuant to Article 8 with respect to a claim described in this
Section 6.3, it shall follow the procedures set forth in Article 8 if it wishes to obtain such indemnification. [ * ]. If necessary in order to avoid infringement of said Third Party intellectual property rights, Helsinn and Exelixis shall
attempt to obtain a license for Helsinn under the Third Party’s intellectual property rights. Royalties to be paid by Helsinn to Exelixis hereunder shall continue to be payable in accordance with the terms and conditions of this Agreement and
any royalties on sales of the Products payable to the Third Party under said license shall be paid by Helsinn. [ * ]. 
  

 18 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 6.4 Patent Terms Extensions. The Parties shall co-operate in filing for and obtaining patent
extensions and supplementary or complementary protection certificates, if available, of the Exelixis Patent Rights. Such co-operation shall include without limitation: (i) advising each other in a timely manner of any action by any Regulatory
Authority or other competent authority that is pertinent to any such extension; (ii) reasonably supplying each other with all information in its Control pertaining to the extension of any such Exelixis Patent Rights; and (iii) co-operating with each
other to prepare and execute all supporting affidavits or documents required in connection with the extension of any such Exelixis Patent Rights. 
  

	7.	REPRESENTATIONS AND WARRANTIES 

  
 7.1 Mutual Warranties. Each Party represents and warrants to the other Party that: (i) it has the authority and right
to enter into and perform this Agreement; (ii) this Agreement is a legal and valid obligation binding upon it and is enforceable in accordance with its terms, subject to applicable limitations on such enforcement based on bankruptcy laws and other
debtors’ rights; and (iii) its execution, delivery and performance of this Agreement will not conflict in any material fashion with the terms of any other agreement or instrument to which it is or becomes a party or by which it is or becomes
bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over it. 
  
 7.2 Exelixis Warranties. Exelixis represents and warrants to Helsinn that: 
  
 7.2.1 Exelixis has the full right and power to [ * ]; 
  
 7.2.2 Exelixis has delivered to Helsinn [ * ]; 
  
 7.2.3 As of the transfer date of each of the Assumed Contracts,
Exelixis has [ * ]; 
  
 7.2.4 As of the Effective
Date, there are no [ * ], other than the [ * ], which would [ * ] and Exelixis will not knowingly [ * ]; 
  
 7.2.5 Exelixis has not entered into any Third Party agreements as of the Effective Date which would materially adversely effect (i) Exelixis’
ability to perform all of the material obligations undertaken by Exelixis hereunder, or (ii) to Exelixis’ knowledge as of the Effective Date, Helsinn’s ability to exploit the license granted hereunder, and Exelixis will not knowingly enter
into any such agreement after the Effective Date; 
  
 7.2.6
(i) As of the Effective Date, Exelixis has not received any written notice or other written communication alleging that Becatecarin infringes or misappropriates the intellectual property rights of a Third Party; (ii) as of the Effective Date,
all [ * ]; (iii) as of the Effective Date, [ * ]; (iv) as of the Effective Date, [ * ]; (v) as of the Effective Date, [ * ]; and (vi) it has [ * ]; 
  
 7.2.7 [ * ]. 
  
 7.2.8 (i) [ * ]; and (ii) [ * ]. 
  

 19 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 7.2.9 [ * ]. 
  
 7.2.10 There is no [ * ] which might in any material way [ * ]. 
  
 7.3 No Additional Representations. 
  
 7.3.1 Helsinn acknowledges that Exelixis, its Affiliates, and its and
their directors, officers, employees, agents or contractors have not made any representation or warranty, expressed or implied, as to the accuracy or completeness of any information, documents or material generated by Third Parties or provided by
Third Parties to Exelixis regarding Becatecarin and its development or commercialization. Exelixis, its Affiliates, and its and their directors, officers, employees, agents or contractors shall not have or be subject to any liability to Helsinn or
any Third Party resulting from the provision to Helsinn, or Helsinn’s use of, any such information, documents or material regardless of how it was made available to Helsinn. 
  
 EXCEPT AS EXPRESSLY SET FORTH IN THE REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTIONS 7.1 AND 7.2 OF THIS AGREEMENT, THERE ARE NO
REPRESENTATIONS OR WARRANTIES BY EXELIXIS OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO BECATECARIN, PRODUCTS OR THE MANUFACTURE OR USE OF BECATECARIN OR PRODUCTS (INCLUDING WITHOUT LIMITATION ITS RESEARCH, DEVELOPMENT (INCLUDING CLINICAL TRIALS)
OR COMMERCIALIZATION) INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE OR USE OF BECATECARIN OR ANY PRODUCT OR ANY REPRESENTATIONS OR WARRANTIES WITH RESPECT TO INFRINGEMENT OF
THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
  

	8.	INDEMNIFICATION 

  
 8.1 Exelixis. Exelixis shall indemnify, defend and hold harmless Helsinn, its Affiliates, and their respective directors, officers and employees
(each a “Helsinn Indemnitee”) from and against any and all liabilities, damages, losses, costs or expenses (including attorneys’ and professional fees and other expenses of litigation and/or arbitration)
(“Liabilities”) resulting from any claim, suit or proceeding made or brought by a Third Party against a Helsinn Indemnitee to the extent arising from or occurring as a result of: (i) any breach by Exelixis of the representations and
warranties set forth in Section 7.1 or 7.2; (ii) any claims based on injury to a Third Party (including death) arising from the use of Products by Exelixis prior to the Effective Date; (iii) any liability retained by Exelixis pursuant to Section
3.3.2; and/or (iv) any negligent or wrongful act or omission hereunder by Exelixis and/or any breach by Exelixis of any of its obligations hereunder, except in each case to the extent that (1) any such Liability was due to the negligence or willful
misconduct of a Helsinn Indemnitee or (2) Helsinn has an obligation under Section 8.2 to indemnify Exelixis for such Liabilities. 
  

 20 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 8.2 Helsinn. Helsinn shall indemnify, defend and hold harmless Exelixis, its Affiliates, and their
respective directors, officers and employees (each an “Exelixis Indemnitee”) from and against any and all Liabilities resulting from any claim, suit or proceeding made or brought by a Third Party against an Exelixis Indemnitee to
the extent arising from or occurring as a result of: (i) any breach by Helsinn of the representations and warranties set forth in Section 7.1; (ii) any use, manufacture, development, distribution, storage, handling, promotion, marketing and sale of
the Product(s) by or for Helsinn or its Affiliates or sublicensees after the Effective Date; (iii) the use of any Products after the Effective Date by any person or entity; (iv) any liability assumed by Helsinn pursuant to Section 3.3.2; and/or (v)
any negligent or wrongful act or omission hereunder by Helsinn and/or any breach by Helsinn of any of its obligations hereunder, except in each case to the extent that (1) any such Liability was due to the negligence or willful misconduct of an
Exelixis Indemnitee or (2) Exelixis has an obligation under Section 8.1 to indemnify Helsinn for such Liabilities. 
  
 8.3 Procedure. A Party seeking indemnification hereunder (an “Indemnitee”) shall promptly notify the other Party (the
“Indemnitor”) in writing of such alleged Liability. The Indemnitor shall have the sole right to control the defense and settlement thereof. The Indemnitee shall cooperate with the Indemnitor and its legal representatives in the
investigation of any action, claim or liability covered by this Article 8. The Indemnitee shall not, except at its own cost and risk, voluntarily make any payment or incur any expense with respect to any claim or suit without the prior written
consent of the Indemnitor, which the Indemnitor shall not be required to give. The Indemnitor shall not be required to provide indemnification with respect to a Liability the defense of which is actually prejudiced by the failure to give notice by
the Indemnitee or the failure of the Indemnitee to cooperate with the Indemnitor or where the Indemnitee settles or compromises a Liability without the written consent of the Indemnitor. Each Party shall cooperate with the other Party in resolving
any claim or Liability with respect to which one Party is obligated to indemnify the other under this Agreement, including without limitation, by making commercially reasonable efforts to mitigate or resolve any such claim or Liability. 

 
 8.4 Limitations on Liability. NOTWITHSTANDING
ANY PROVISION HEREIN, A PARTY SHALL IN NO EVENT BE LIABLE TO
THE OTHER PARTY OR ITS AFFILIATES, OFFICERS, DIRECTORS, EMPLOYEES, STOCKHOLDERS,
AGENTS OR REPRESENTATIVES FOR ANY INDIRECT, CONSEQUENTIAL OR PUNITIVE DAMAGES
(INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF USE, DAMAGE TO
GOODWILL OR LOSS OF BUSINESS), UNLESS SUCH DAMAGES: (I) ARE OWED
UNDER THE LIABLE PARTY’S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 8; (II) ARE
DUE TO THE LIABLE PARTY’S BREACH OF ARTICLE 5; OR (III) ARE
DUE TO THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THE LIABLE
PARTY. 
  

	9.	TERM AND TERMINATION 

  
 9.1 Term. Subject to the provisions below in this Section 9, the term of this Agreement shall commence on the
Effective Date and continue on a country-by-country basis until the expiration of all Helsinn’s royalties payment obligations under this Agreement, unless earlier terminated pursuant to Section 9.2 or 9.3. On such expiration, Helsinn’s
license under Section 2.1 with respect to Exelixis Know-How shall survive as a fully-paid and royalty-free license. 
  

 21 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 9.2 Material Breach. If any Party has breached any of its material obligations hereunder, and such
breach has continued for [ * ] days after written notice thereof was provided to the breaching Party by the non-breaching Party, the non-breaching Party may terminate this Agreement. Any termination shall become effective at the end of such
[ * ] day period unless the breaching Party has cured any such breach prior to the expiration of the [ * ] day period. For the avoidance of doubt, if Exelixis fails to supply Helsinn with [ * ] of Becatecarin for Injection by 30
April 2006 and this failure prevents Helsinn from enrolling additional human subjects, or from maintaining the then-current enrollment, in the Phase 3 Clinical Trial of the Product that is ongoing at the Effective Date, then this failure shall be
considered a material breach by Exelixis entitling Helsinn to avail itself of the remedies set forth at Section 9.4.2 below. 
  
 9.3 Relinquishment by Helsinn. Beginning twelve (12) months after the Effective Date, Helsinn may relinquish all the rights and the license granted
to it under this Agreement and thereby terminate this Agreement, at any time, by giving Exelixis written notice of its desire to do so at least six (6) months prior to the date on which the rights and the license are desired to be terminated. Such
termination shall be conditional upon Helsinn informing Exelixis in writing, together with the notice of termination, that, in Helsinn’s reasonable business judgment based on scientific or economic evidence, it is impossible for Helsinn to
carry out further development or marketing of the Product in the Territory. 
  
 9.4 Effect of Termination or Expiration. Termination or expiration of this Agreement for any reason shall not release either Party hereto from any liability which, at the time of such termination or expiration,
has already accrued to the other Party or which is attributable to a period prior to such termination or expiration or preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any
breach of, or default under, this Agreement. It is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching Party may be entitled to specific performance as a partial
remedy for any such breach. 
  
 9.4.1 Effects of certain
terminations attributable to Helsinn. 
  
 (a) If this
Agreement is terminated by Exelixis pursuant to Section 9.2 for Helsinn’s failure to pay any of the amounts owed to Exelixis under Article 4 (and such failure is not due to any breach by a sublicensee of Helsinn), then Exelixis may pursue all
remedies available to it under law or equity, and: (i) Helsinn shall transfer and assign to Exelixis all Information in its possession relating to the Product, and all regulatory filings (including any regulatory approvals) in Helsinn’s name,
agreements with Third Parties (subject to Section 9.4.1(a)(ii)), trademark and other intellectual property rights, and supplies of Product (including any intermediates, retained samples and reference standards) that in each case are in its Control
and that relate to the Product; (ii) with respect to each of Helsinn’s sublicensees who are not in breach of their agreements relating to the Product, Exelixis shall notify Helsinn in writing if, in Exelixis’ reasonable business judgment,
Exelixis desires that the agreements with such sublicensees be transferred and assigned to Exelixis or that the relations between each said sublicensee and Exelixis be regulated by any other contract which Exelixis and the sublicensee may deem
appropriate; and (iii) Helsinn undertakes, upon Exelixis’ written request, to supply the Products in accordance with Exelixis’ and/or the sublicensees’ requirements, at market prices. 
  

 22 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Any transfer and assignment by Helsinn to Exelixis under Section 9.4.1(a)(i) shall be free of charge to Exelixis (except
for administrative costs and fees connected with the transfer of trademarks and other intellectual property rights, which shall be borne by Exelixis) and shall occur in a manner consistent with Exelixis’ transfer of Exelixis Know-How, Assumed
Contracts and Product inventory to Helsinn under Article 3. Notwithstanding anything to the contrary, Exelixis shall have no obligation (either under Section 9.4.1(a)(ii) or otherwise under this Agreement) to be transferred or assigned any
agreements from, or enter into any relations with, any of Helsinn’s sublicensees who are in breach of their agreements with Helsinn at the time of Exelixis’ termination of this Agreement. 
  
 (b) If this Agreement is terminated by Helsinn pursuant to Section
9.3, then: (i) Helsinn shall transfer and assign to Exelixis all Information in its possession relating to the Product, and all of the regulatory filings (including any regulatory approvals) in Helsinn’s name, agreements with Third Parties
(subject to Section 9.4.1(b)(ii)), trademark and other intellectual property rights, and supplies of Product (including any intermediates, retained samples and reference standards) that in each case are in its Control and that relate to the Product;
(ii) Exelixis shall notify Helsinn in writing if, in Exelixis’ reasonable business judgment, Exelixis desires to continue the development and/or commercialization of the Product, in which case Helsinn’s sublicensees’ rights on the
Product shall survive termination hereof and shall be varied into a direct grant from Exelixis (but only if such sublicensee is not in breach of its existing agreement with Helsinn), being however understood that the relations between each said
sub-licensee and Exelixis shall, in Exelixis’ sole discretion, be regulated either by the agreement in force between Helsinn and the sublicensee, which in such case would be assigned to Exelixis, or by any other contract which Exelixis and the
sublicensee may deem appropriate; and (iii) Helsinn undertakes, upon Exelixis’ written request, to supply the Products in accordance with Exelixis’ and/or the sublicensees’ requirements, at market prices. Any transfer and assignment
by Helsinn to Exelixis under Section 9.4.1(b)(i) shall be free of charge to Exelixis (except for administrative costs and fees connected with the transfer of trademarks and other intellectual property rights, which shall be borne by Exelixis) and
shall occur in a manner consistent with Exelixis’ transfer of Exelixis Know-How, Assumed Contracts and Product inventory to Helsinn under Article 3. Notwithstanding anything to the contrary, Exelixis shall have no obligation (either under
Section 9.4.1(b)(ii) or otherwise under this Agreement) to be transferred or assigned any agreements from, or enter into any relations with, any of Helsinn’s sublicensees who are in breach of their agreements with Helsinn at the time of
Helsinn’s termination of this Agreement. 
  
 9.4.2
Effects of other termination. In the event of any termination that is not described in Section 9.4.1, the applicable Party may pursue all remedies available to such Party under law or equity pursuant to Sections 10.3 or 10.4, as applicable. In
particular, in case of breach by Exelixis as described at Section 9.2, Helsinn in its discretion (i) shall have the right to terminate this Agreement and shall be entitled to receive appropriate (as determined by an arbitrator pursuant to Section
10.3) compensation from Exelixis as a result of the damages suffered by Helsinn from such breach, or (ii) as an alternative to its right to terminate this Agreement, Helsinn may elect to continue this Agreement and to reduce the royalty rates for
the remaining term of this Agreement to [ * ]. 
  

 23 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 9.5 Survival. The following provisions of this Agreement shall survive expiration or termination
of this Agreement for any reason: Articles 1, 5, 8 and 10, and Sections 3.3.2, 4.8, 9.4, and 9.5. 
  
 9.6 Rights in Bankruptcy. All rights and the license granted under or pursuant to this Agreement by Exelixis are, and shall otherwise be deemed to
be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the United States Bankruptcy Code. The Parties agree that Helsinn, as licensee of such
rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the United States Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against
Exelixis under the United States Bankruptcy Code, Helsinn shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in
Helsinn’s possession, shall be promptly delivered to it: (a) upon any such commencement of a bankruptcy proceeding upon Helsinn’s written request therefor, unless Exelixis continues to perform all of its obligations under this Agreement;
or (b) if not delivered under Section 9.6(a) above, following the rejection of this Agreement by or on behalf of Exelixis. 
  

	10.	MISCELLANEOUS  

  
 10.1 Complete Agreement; Modification. This Agreement, along with the Assumed Contracts and the Mutual Non-Disclosure Agreement between the Parties
effective April 1, 2004, constitute the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, expressed or
implied, are superseded hereby, merged and canceled, and are null and void and of no effect. No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and duly executed
on behalf of both Parties. 
  
 10.2 Governing Law.
Resolution of all disputes arising out of or related to this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the
State of Delaware, without regard to conflicts of law rules requiring the application of different law. 
  
 10.3 Dispute Resolution. Subject to Section 10.4, in the event of any dispute, controversy or claim between the Parties relating to or arising out
of this Agreement (a “Dispute”), each Party shall use its reasonable efforts to expeditiously settle the Dispute in an amicable manner within a time reasonable under the circumstances. In the absence of a settlement, either Party
may refer such Dispute to the Chief Executive Officers of, or such other senior executive officers designated by, each respective Party for resolution. If such senior executive officers fail to reach a resolution within [ * ] days of such
referral, or such other period as the Parties may agree, then such Dispute shall be decided by arbitration to be conducted in Washington D.C., in accordance with the International Rules of the American Arbitration Association for Commercial
Arbitration in effect at the time the Dispute arises, unless the Parties mutually agree otherwise. Each Party shall be responsible for its own costs (including, without limitation, reasonable attorneys’ fees) and expenses in connection with any
arbitration proceeding under this Section 10.3.  
  

 24 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 10.4 Patents. Any dispute, controversy or claim relating to the scope, validity, enforceability or
infringement of any Exelixis Patent Rights covering the manufacture, use or sale of any Products shall be submitted to a court of competent jurisdiction in the territory in which such Patent or trademark rights were granted or arose. 
  
 10.5 Performance by Affiliates/Subcontractors. Each Party acknowledges
that its obligations under this Agreement may be performed by its respective Affiliates or subcontractors. Notwithstanding any delegation of obligations under this Agreement by a Party to an Affiliate or subcontractor, each Party shall remain
primarily liable and responsible for the performance of all of its obligations under this Agreement and for causing its Affiliates and/or subcontractors to act in a manner consistent herewith. Wherever in this Agreement the Parties delegate
responsibility to Affiliates, subcontractors or local operating entities, the Parties agree that such entities shall not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way.

  
 10.6 Consents Not Unreasonably Withheld or Delayed.
Whenever provision is made in this Agreement for either Party to secure the consent or approval of the other, that consent or approval shall not unreasonably be withheld or delayed, and whenever in this Agreement provisions are made for one Party to
object to or disapprove a matter, such objection or disapproval shall not unreasonably be exercised. 
  
 10.7 Maintenance of Records. Each Party shall keep and maintain all records required by law or regulation with respect to Products and shall make
copies of such records available to the other Party upon request. 
  
 10.8 Independent Contractors. The relationship of the Parties hereto is that of independent contractors. The Parties hereto are not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this
Agreement or the transactions contemplated thereby. At no time shall any Party make commitments or incur any charges or expenses for or in the name of the other Party. 
  
 10.9 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without
the prior written consent of the other, except a Party may make such an assignment without the other Party’s consent to an Affiliate or to a successor to substantially all of the business of such Party to which this Agreement relates, whether
in a merger, sale of stock, sale of assets or other transaction; provided, that any such permitted successor or assignee of rights and/or obligations hereunder shall, in a writing to the other Party, expressly assume performance of such rights
and/or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 10.9 shall be null and void and of no legal
effect. 
  
 10.10 Notices. Any notices given under this
Agreement shall be in writing, addressed to the Parties at the following addresses, and delivered by person, by facsimile, or by FedEx or 
  

 25 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 other reputable international courier service. Any such notice shall be deemed to have been given as of the day of
personal delivery, one (1) day after the date sent by facsimile service or on the day of successful delivery to the other Party confirmed by the courier service. 
  

			
	 For Exelixis:
	 	Exelixis, Inc.
	 	 	170 Harbor Way
	 	 	P.O. Box 511
	 	 	South San Francisco, CA 94083
	 	 	Attention: VP, Legal Affairs
	 	 	Phone: +1 650-837-7950
	 	 	Fax: +1 650-837-7951
		
	 With a copy to:
	 	Cooley Godward LLP
	 	 	Five Palo Alto Square
	 	 	3000 El Camino Real
	 	 	Palo Alto, CA 94306
	 	 	Attention: Robert L. Jones, Esq.
	 	 	Phone: +1 650-843-5000
	 	 	Fax: +1 650-849-7400
		
	 For Helsinn:
	 	Helsinn Healthcare S.A.
	 	 	via Pian Scairolo 9
	 	 	6912 Lugano
	 	 	Switzerland
	 	 	Attention: Director, Legal Affairs
	 	 	Phone: +41 91 985.21.21
	 	 	Fax: +41 91 993.21.22

  
 10.11 Force
Majeure. Each Party shall be excused from the performance of its obligations (other than payment obligations) under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides
notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement,
force majeure shall include conditions beyond the control of the Parties, including without limitation, an act of God, voluntary or involuntary compliance with any regulation, law or order of any government, war, act of terrorism, civil commotion,
labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe; provided, however, the payment of invoices due and owing
hereunder shall not be delayed by the payer because of a force majeure affecting the payer. 
  
 10.12 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement. 
  

 26 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 10.13 Severability. In the event that any provision of this Agreement is determined to be invalid
or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision to any possible extent. In such event, the Parties shall in good faith negotiate a substitute clause
for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the Parties in entering this Agreement. 
  
 10.14 Waiver. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of
this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in
writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. 
  
 10.15 Cumulative Rights. The rights, powers and remedies hereunder shall be in addition to, and not in limitation of, all rights, powers and
remedies provided at law or in equity, or under any other agreement between the Parties. All of such rights, powers and remedies shall be cumulative, and may be exercised successively or cumulatively. 
  
 10.16 Use of Name. Except as required by law, neither Party shall use
the name or trademarks of the other Party for any advertising or promotional purposes without the prior written consent of such other Party. 
  
 10.17 Construction of the Agreement. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural
the singular, the use of any gender will be applicable to all genders, and the word “or” are used in the inclusive sense. When used in this Agreement, “including” means “including, without limitation,.” References to
either Party include the successors and permitted assigns of that Party. The headings of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any
provision contained in this Agreement. The Parties have each consulted counsel of their choice regarding this Agreement, and, accordingly, no provisions of this Agreement will be construed against either Party on the basis that the Party drafted
this Agreement or any provision thereof. If the terms of this Agreement conflict with the terms of any Exhibit, then the terms of this Agreement shall govern. The official text of this Agreement and any Exhibits hereto, any notice given or accounts
or statements required by this Agreement, and any dispute proceeding related to or arising hereunder, shall be in English. In the event of any dispute concerning the construction or meaning of this Agreement, reference shall be made only to this
Agreement as written in English and not to any other translation into any other language. 
  
 10.18 Insurance. Each Party agrees to procure and maintain, in full force and effect during the term of this Agreement, insurance from insurers of recognized financial responsibility, against such losses and
risks and in such amounts which, in such Party’s reasonable judgment, are prudent and customary in the business in which it is engaged. Each Party shall promptly supply the other Party, upon the other Party written request, with a copy of the
certificate of insurance evidencing said coverage. 
  

 27 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 10.19 Mitigation. Each of the Parties hereto shall take commercially reasonable steps to avoid or
mitigate any loss, damage or liability which might give rise to a claim under this Agreement.  
  
 10.20 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which shall
constitute together the same document. Counterparts may be signed and delivered by facsimile, each of which shall be binding when sent. 
  
 [Signature Page Follows] 
  

 28 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IN WITNESS WHEREOF, Exelixis and
Helsinn have executed this Agreement by their respective duly authorized representatives as of the Effective Date. 
  

					
	EXELIXIS, INC.	 	 	 	HELSINN HEALTHCARE S.A.
			
	By: /s/ George Scangos	 	 	 	By: /s/ Riccardo Braglia
			
	Name: George Scangos	 	 	 	Name: Riccardo Braglia
			
	Title: President and CEO	 	 	 	Title: Managing Director
			
	 	 	 	 	By: /s/ Enrico Braglia
			
	 	 	 	 	Name: Enrico Braglia
			
	 	 	 	 	Title: Managing Director

  

 29 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 1.2 
  
 ASSUMED CONTRACTS 
  
 [ * ] 
  

 30 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 1.7 
  
 EXELIXIS PATENTS 
  
 [ * ] 
  

 31 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT 2.7 
  
 List of XL119-001 Non-US Regulatory Reference Numbers 
  
 [ * ] 
  

 32 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Exhibit 5.4 
 Press Release 
  
 EXELIXIS AND HELSINN SIGN AGREEMENT 
 FOR XL119 (BECATECARIN) 
  
 SOUTH SAN FRANCISCO, Calif and Lugano, Switzerland- May XX, 2005—Exelixis, Inc. (Nasdaq:
EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition,
Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis has granted to Helsinn a world-wide, royalty-bearing license to XL119. Exelixis has retained rights to reacquire commercial rights to XL119 for North America,
and will receive milestones and royalties on sales in the rest of the world. 
  
 “We are gratified that we have found an excellent partner for the development of XL119,” said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. “Helsinn is a high-quality company with experience in
cancer drug development, as demonstrated by their successful development and licensing of Aloxi® to MGI Pharma. By combining our resources with those of an excellent European partner, we hope to make XL119 available to patients in need around the world. This agreement will free up
substantial financial and product development resources, allowing Exelixis to focus on the Phase I and II trials for our internally-developed pipeline. At the same time, we have structured this deal with rights to reacquire the commercial rights to
XL119 for North America, which is our primary market. I believe that this is an excellent transaction and represents a win for both companies,” said Dr. Scangos. 
  
 “Exelixis has a very strong scientific foundation and we are pleased to be in a partnership with such a company,” said Enrico
Braglia, Managing Director of Helsinn. “Through the development of XL119, we aim to create a new standard of care for patients with biliary tract cancers, a rare and aggressive form of cancer with a high medical need and very limited survival.
While some existing therapies have been used off-label to treat this type of tumor, there is currently no drug therapy that has been approved by regulatory authorities for this indication. We believe that XL119 will offer a meaningful therapeutic
benefit over currently used therapies and will become the therapy of reference for biliary tract cancer patients worldwide,” 
  
 XL119 is currently in a multi-national Phase III clinical trial at approximately 50 centers in North America and Europe. The primary endpoint of the 600-patient trial is
increased survival of patients with bile duct tumors treated with XL119 compared with the chemotherapy agents 5-fluorouracil (FU) and leucovorin. The trial is currently recruiting and enrolling patients as anticipated and is on track to be completed
as planned. XL119 was granted the Orphan Drug designation in the USA on March 1, 2004. 
  
 About Exelixis 
  
 Exelixis, Inc. is a leading genomics-based
drug discovery company dedicated to the discovery and development of novel therapeutics across various disease areas. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline.
Exelixis’ development pipeline covers cancer and metabolism and is comprised of the following compounds: XL784, initially an anticancer compound, which completed a Phase I clinical trial and is being developed as a treatment for 
  

 33 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 renal disease; XL647, XL999 and XL880, anticancer compounds currently in Phase I clinical trials; XL820 and XL844,
anticancer compounds for which INDs have been filed; XL184 a potential IND candidate for the treatment of cancer; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders.
Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between
Exelixis and GSK, GSK has the option, after completion of Phase IIa clinical trials, to elect to develop a certain number of compounds in Exelixis’ product pipeline, which may include the cancer compounds identified in this press release (other
than XL119), thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis. For more information, please visit the company’s web site at www.exelixis.com. 
  
 About HELSINN HEALTHCARE 
  
 HELSINN HEALTHCARE SA is a privately owned pharmaceutical group with headquarters in
Switzerland. HELSINN’s core business is the licensing of pharmaceuticals in niche therapeutic areas. The company’s business strategy is to in-license early-stage new chemical entities and complete their development from the performance of
pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic markets (U.S. and Europe). HELSINN’s products are eventually out-licensed to its marketing partners for distribution. The active pharmaceutical
ingredients and the finished dosage forms are manufactured at HELSINN’s cGMP facilities and supplied worldwide to its customers. For more information about HELSINN, please visit www.helsinn.com 
  
 This press release contains forward-looking statements, including without limitation all
statements related to Exelixis’ potential to receive future payments related to the clinical development program for XL119, the potential success of the XL119 Phase III trial, the therapeutic and commercial potential of XL784, XL647, XL880,
XL999, XL820, XL844 and XL184, other compounds in the Exelixis preclinical pipeline and its program in metabolic diseases. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,”
“will,” “slated,” “goal” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis’ current expectations. Forward-looking statements
involve risks and uncertainties. Exelixis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without
limitation, the ability of the company to successfully conduct the clinical trials for, XL647, XL999 and XL880; the ability of the company to advance additional preclinical compounds into clinical development; the uncertainty of the FDA approval
process; and the therapeutic and commercial value of the company’s compounds. These and other risk factors are discussed under “Risk Factors” and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 31, 2005,
annual report on Form 10-K for the year ended December 31, 2004 and other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. 
  
 ### 
  
 Exelixis and the Exelixis logo are registered U.S. trademarks. 
  

			
	Contacts:	  	 
		
	CHARLES BUTLER	  	ALEX BOSSI
	Associate Director,	  	Director,
	Corporate Communications	  	Business Development
	+1 (650) 837-7277	  	+41 (0)91 985 2121
	cbutler@exelixis.com	  	ba@helsinn.com
	537406 v2/HN	  	 

  

 34 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.Novated and Restated Technology License Agreement

 Exhibit 10.4 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
  
 NOVATED AND RESTATED 
  
 TECHNOLOGY LICENSE AGREEMENT 
  
  
 dated as of June 9, 2005 
  
  
 among 
  
  
 EXELIXIS, INC., 
  
  
 SYMPHONY EVOLUTION, INC. 
  
  
 and 
  
  
 SYMPHONY EVOLUTION HOLDINGS LLC 
  

 Table of Contents 
  

					
	 	 	 	  	Page

	 Article  1
	 	Definitions	  	1
			
	 Article  2
	 	Grant Of Rights	  	1
			
	              2.1.
	 	  Assignment	  	1
	              2.2.
	 	  License Grant	  	2
	              2.3.
	 	  Sublicense to Licensor	  	2
	              2.4.
	 	  Right to Sublicense	  	2
	              2.5.
	 	  Partial Reversion of License upon Licensor’s Exercise of Program Option or Discontinuation Option	  	3
	              2.6.
	 	  Reservation of Rights	  	3
	              2.7.
	 	  Regulatory Files	  	4
	              2.8.
	 	  Delivery of Materials	  	4
	              2.9.
	 	  License Opportunities	  	4
	              2.10.
	 	  Separate Third Party License for Discontinued Program	  	5
			
	 Article  3
	 	Sublicense To Certain Third Party Intellectual Property	  	6
			
	              3.1.
	 	  General	  	6
	              3.2.
	 	  Option to Acquire Sublicense	  	6
	              3.3.
	 	  Prosecution Fees	  	6
	              3.4.
	 	  Termination or Amendment of University Agreements	  	6
	              3.5.
	 	  No Conflicts	  	7
			
	 Article  4
	 	Intellectual Property	  	7
			
	              4.1.
	 	  Ownership	  	7
	              4.2.
	 	  Marking	  	7
	              4.3.
	 	  Prosecution and Maintenance	  	7
	              4.4.
	 	  Abandonment	  	8
	              4.5.
	 	  Infringement	  	8
	              4.6.
	 	  First Enforcement Right During Term	  	9
	              4.7.
	 	  Post-Term Enforcement	  	9
	              4.8.
	 	  Withdrawal of Enforcement	  	10
	              4.9.
	 	  Recoveries	  	10
	              4.10.
	 	  Third Party Rights	  	10
			
	 Article  5
	 	Representations And Warranties	  	10
			
	              5.1.
	 	  Representations and Warranties of Licensor	  	10
	              5.2.
	 	  Disclaimer and Acknowledgement	  	11
			
	 Article  6
	 	Indemnification And Limitation Of Liability	  	11
			
	              6.1.
	 	  Indemnity	  	11
	              6.2.
	 	  Notice of Claims	  	12
	              6.3.
	 	  Defense of Proceedings	  	13
	              6.4.
	 	  Settlement	  	14

  

 i 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

					
	              6.5.
	 	  Limitation of Liability	  	14
	              6.6.
	 	  Insurance	  	14
			
	 Article  7
	 	Term And Termination	  	15
			
	              7.1.
	 	  Term	  	15
	              7.2.
	 	  Termination	  	15
	              7.3.
	 	  Survival	  	15
	              7.4.
	 	  Bankruptcy	  	15
			
	 Article  8
	 	Miscellaneous	  	15
			
	              8.1.
	 	  Notices	  	15
	              8.2.
	 	  Entire Agreement	  	16
	              8.3.
	 	  Assignment	  	16
	              8.4.
	 	  Headings	  	17
	              8.5.
	 	  Independent Contractor	  	17
	              8.6.
	 	  Severability	  	17
	              8.7.
	 	  No Third-Party Beneficiaries	  	17
	              8.8.
	 	  Compliance with Laws	  	17
	              8.9.
	 	  Amendment	  	17
	              8.10.
	 	  Governing Law; Consent to Jurisdiction and Service of Process	  	17
	              8.11.
	 	  Waiver Of Jury TriaL	  	18
	              8.12.
	 	  Counterparts	  	18
	              8.13.
	 	  No Waiver	  	18

  

 ii 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 NOVATED AND RESTATED 
 TECHNOLOGY LICENSE AGREEMENT 
  
 This NOVATED AND RESTATED TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made and effective as of June 9, 2005 (the “Effective Date”) by and among, Exelixis Inc., a Delaware corporation
(the “Licensor”), Symphony Evolution, Inc., a Delaware corporation (“Symphony Evolution”) (each of Licensor and Symphony Evolution being a “Party,” and collectively, the
“Parties”), and Symphony Evolution Holdings LLC, a Delaware limited liability company (“Holdings”). 
  
 WHEREAS, Licensor and Holdings have entered into that certain Technology License Agreement, dated June 9, 2005 (the “Original
Agreement”); 
  
 WHEREAS, Holdings desires to assign
its right, title and interest in, and delegate and novate its obligations under the Original Agreement to Symphony Evolution, and Licensor and Symphony Evolution desire to novate and restate the terms and conditions of the Original Agreement to
effect such novation; 
  
 WHEREAS, Licensor owns or has rights in
certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of XL647, XL784, and XL999 and/or the Products; 
  
 WHEREAS, Licensor desires to grant to Symphony Evolution, and Symphony Evolution desires to acquire, the exclusive right to
use such technology, know-how, patents and other intellectual property rights to develop and commercialize Products on the terms and conditions of this Agreement; and 
  
 WHEREAS, Licensor desires to receive, and Symphony Evolution desires to grant to Licensor, the exclusive right to use such
technology, know-how, patents and other intellectual property rights to develop Products on behalf of Symphony Evolution on the terms and conditions of this Agreement. 
  
 NOW THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 Capitalized terms used herein and not defined shall have the meanings
assigned to such terms in Annex A attached hereto. 
  
 ARTICLE 2 
 GRANT OF RIGHTS 
  
 2.1. Assignment. Holdings hereby assigns to Symphony Evolution all of its right, title and interest in and to the
Original Agreement. The Parties agree that from and after the Effective Date, all of the right, title, interest and obligations of Holdings under the Original Agreement will be assigned, novated and transferred to, and assumed by, Symphony
Evolution, as amended and restated by this Agreement. 
  

 1 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 2.2. License Grant. Subject to Sections 2.3, 2.4 and 2.6 below, Licensor hereby grants to Symphony
Evolution, subject to the terms and conditions of this Agreement, a fully paid, worldwide, exclusive (even as to Licensor) license under the Licensed Intellectual Property, to develop, make, have made, use, offer for sale, sell, and import XL647,
XL784, XL999 and Products. 
  
 2.3. Sublicense to Licensor.
Symphony Evolution hereby grants to Licensor a fully paid, worldwide, exclusive (even as to Symphony Evolution) sublicense under the Licensed Intellectual Property, with the right to grant further sublicense(s), to develop, make, have made, use and
import XL647, XL784, XL999 and Products, or otherwise as necessary or useful to carry out Licensor’s obligations or exercise Licensor’s rights under the Operative Documents. Notwithstanding the foregoing, Licensor shall only exercise its
sublicense rights in connection with and for the purpose of carrying out Licensor’s obligations or exercising Licensor’s rights under the Operative Documents. In the event of the expiration of a Discontinuation Option without exercise by
Licensor, the sublicense set forth in this Section 2.3 shall expire with respect to the compounds and Products relating to the Program to which such Discontinuation Option pertained. Upon expiration of the Term without Licensor’s exercise of
the Purchase Option, the sublicense set forth in this Section 2.3 shall expire with respect to all compounds and Products relating to the Program(s) for which Licensor has not exercised the Program Option or Discontinuation Option. 
  
 2.4. Right to Sublicense. The license granted hereunder includes the
right of Symphony Evolution to grant sublicenses under the Licensed Intellectual Property, provided, that, 
  
 (a) subject to Sections 2.3 and 2.4(b), Symphony Evolution shall not sublicense any of the rights granted pursuant to Section 2.2 to any third party
(including without limitation any Affiliates) during the Term; 
  
 (b) notwithstanding (a), in the event of the expiration of a Discontinuation Option without exercise by Licensor, Symphony Evolution may grant sublicense(s) to third parties (including without limitation Affiliates) of the rights granted
pursuant to Section 2.2 with respect to the compounds and Products relating to the Program to which such Discontinuation Option pertained, provided that Symphony Evolution acts in accordance with Section 11.2(b) of the Amended and Restated Research
and Development Agreement; 
  
 (c) each sublicense granted is (i)
pursuant to a written contract, (ii) consistent with the terms of this Agreement, (iii) does not grant any rights beyond the scope of the license rights granted herein, and (iv) is as protective of Licensor’s rights as set forth in this
Agreement; and 
  
 (d) upon Licensor’s written request,
Symphony Evolution shall provide to Licensor copies of any sublicense agreements, provided that (i) Symphony Evolution may redact any financial or other proprietary information contained therein which does not affect Licensor’s 
  

 2 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 rights and (ii) Licensor shall treat its copy of the sublicense agreements as Confidential Information of Symphony
Evolution, provided that, if Symphony Evolution exercises its option in Section 3.2, Licensor may disclose such sublicense agreement or the material terms thereof as necessary to fulfill its obligations under the Yale Agreement or Regents Agreement,
as applicable. 
  
 2.5. Partial Reversion of License upon
Licensor’s Exercise of Program Option or Discontinuation Option. Licensor and Symphony Evolution acknowledge that Licensor may exercise its Program Option pursuant to Section 11.1 of the Amended and Restated Research and Development
Agreement, or its Discontinuation Option pursuant to Section 11.2 of the Amended and Restated Research and Development Agreement. Upon the Program Option Closing Date or the Discontinuation Option Closing Date, as applicable, (i) the license set
forth in Section 2.2 (and the corresponding sublicense under Section 2.3) shall expire with respect to the compounds and Products relating to the Program for which Licensor exercised its Program Option or Discontinuation Option, as applicable, (ii)
those patents, know-how and enhancements that were previously part of the Licensed Intellectual Property and relate to such Program (including its compounds and Products) but not to the other Programs, shall be deleted from the relevant intellectual
property definitions, and accordingly, Symphony Evolution shall no longer be responsible for any obligations or costs (including royalties or fees to third parties, prosecution costs, maintenance costs and enforcement costs) with respect to such
patents, know-how and enhancements; and (iii) Symphony Evolution shall (a) at Licensor’s request and option, promptly return to Licensor or destroy all Tangible Materials relating solely to such Program; and (b) upon Licensor’s request,
provide Licensor a copy of any Tangible Materials which relate to such Program (but not solely to such Program). The Parties shall, as necessary, promptly amend this Agreement, in connection with the exercise and consummation of the Program Option
pursuant to Section 11.1 or the Discontinuation Option pursuant to Section 11.2 of the Amended and Restated Research and Development Agreement, to give Licensor all rights it needs to pursue the Program for which such option was exercised without
any obligation to or dependency on Symphony Evolution and to limit this Agreement to the other Programs. 
  
 2.6. Reservation of Rights. All rights not expressly granted to a Party hereunder shall remain the exclusive property of the other Party.
Notwithstanding the exclusivity of the license granted to Symphony Evolution in Section 2.2, Licensor retains the right to make and use XL647, XL784, XL999 and Structurally Related Compounds solely for Licensor’s research purposes. Symphony
Evolution covenants and agrees not to use or exploit the Licensed Intellectual Property outside of the scope of the licenses granted herein. Licensor covenants and agrees not to use or exploit the Licensed Intellectual Property in connection with
the development, manufacture, use, sale, or importation of XL647, XL784, XL999 or Products after the expiration of all sublicenses granted pursuant to Section 2.3; provided, however, that such covenant by Licensor shall not (a) apply to any Program
for which Licensor exercises a Program Option or Discontinuation Option or to any compounds or Products relating to such Program or (b) restrict Licensor’s ability to practice the retained rights specified in this Section 2.6. 
  

 3 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 2.7. Regulatory Files. 
  
 (a) Within a reasonable time after the expiration or termination of the Purchase Option without exercise by Licensor and as
of a date to be agreed upon by Licensor and Symphony Evolution, Licensor and Symphony Evolution shall, at Symphony Evolution’s expense, take all actions necessary to effect the assignment to Symphony Evolution or its designee of the sponsorship
to the Regulatory Files with respect to the Programs for which Licensor has not exercised its Program Option or Discontinuation Option. After such Regulatory Files are assigned to Symphony Evolution, Licensor shall have no further rights therein or
obligations thereunder. Licensor shall, at the reasonable request of Symphony Evolution and at Symphony Evolution’s expense, perform any acts that Symphony Evolution may reasonably deem necessary or desirable to evidence or confirm Symphony
Evolution’s ownership interest in such Regulatory Files, including, but not limited to, making further written assignments in a form determined by Symphony Evolution. Without limiting the license rights granted under this ARTICLE 2, the Parties
understand and agree that the assignment of such Regulatory Files does not include an assignment of any Licensed Intellectual Property. 
  
 (b) In the event of the expiration of a Discontinuation Option without exercise by Licensor, the provisions of Section 2.7(a) shall apply solely with
respect to the Regulatory Files for the Program to which the Discontinuation Option pertained. 
  
 2.8. Delivery of Materials. 
  
 (a) Upon the expiration or termination of the Purchase Option without exercise by Licensor, Licensor shall, at Symphony Evolution’s expense, promptly deliver to Symphony Evolution all copies of Tangible Materials existing as of the
date of such expiration or termination that relate to the Programs for which Licensor has not exercised its Program Option or Discontinuation Option; provided, however that Licensor may also retain copies of (and the right to use) those Tangible
Materials that are required to be delivered to Symphony Evolution hereunder but which also relate to (i) any Program for which Licensor has exercised its Program Option or Discontinuation Option or (ii) any other product of Licensor. 
  
 (b) In the event of the expiration of a Discontinuation Option without
exercise by Licensor, Licensor shall, at Symphony Evolution’s expense, promptly deliver to Symphony Evolution all copies of Tangible Materials existing as of the date of such expiration that relate to the Program to which the Discontinuation
Option pertained; provided, however that Licensor may also retain copies of (and the right to use) those Tangible Materials that are required to be delivered to Symphony Evolution hereunder but which also relate to any other Program or any other
product of Licensor. 
  
 2.9. License Opportunities. In the
event that, during the Term, Licensor reasonably determines that it is necessary to license from any third party any intellectual property relating to the composition of matter, use, manufacture, formulation or exploitation of XL647, XL784, or XL999
or the Products (“Third Party IP”) and Licensor desires to license such Third Party IP during the Term, then (i) if Licensor desires Symphony Evolution to pay any or all of the financial obligations under such license,
Licensor shall obtain Symphony Evolution’s written consent, which shall not be unreasonably withheld or delayed 
  

 4 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 before acquiring such license; and (ii) if Symphony Evolution provides such consent, then unless otherwise agreed to by
the Parties in writing, Licensor shall use commercially reasonable efforts to obtain, at the time such license is granted, the right to sublicense such Third Party IP to Symphony Evolution consistent with the terms of this Agreement as if such Third
Party IP were Licensed Intellectual Property. Unless otherwise agreed to by the Parties in writing, the financial obligations under any licenses to Third Party IP obtained by Licensor with Symphony Evolution’s consent shall (1) be borne fully
by Symphony Evolution if such Third Party IP relates solely to the composition of matter, use, manufacture, formulation or exploitation of XL647, XL784, or XL999 or the Products and, at the time of entering into such third party license, Licensor
has not exercised its Program Option or Discontinuation Option with respect to the Program to which such Third Party IP relates; or (2) be shared by the Parties in amounts and/or percentages to be agreed upon by the Parties prior to Licensor
entering into such third party license, if such Third Party IP relates (but does not relate solely) to the composition of matter, use, manufacture, formulation or exploitation of Products within Program(s) for which Licensor has not exercised its
Program Option and/or Discontinuation Option and also relates to either (x) the composition of matter, use, manufacture, formulation or exploitation of Products within Program(s) for which Licensor has exercised its Program Option and/or
Discontinuation Option or (y) the composition of matter, use, manufacture, formulation or exploitation of other products of Licensor; or (3) be borne fully by Licensor if such Third Party IP relates solely to the composition of matter, use,
manufacture, formulation or exploitation of a Product(s) within a Program(s) for which Licensor has exercised its Program Option and/or Discontinuation Option. Notwithstanding the foregoing, Licensor shall have no obligation to obtain any such third
party licenses under this Agreement or, in the event that Symphony Evolution does not give such consent, to grant any sublicenses to Symphony Evolution. Upon obtaining a license to such Third Party IP and the right to sublicense to Symphony
Evolution, the Parties will, as necessary, promptly amend this Agreement to include such sublicensed intellectual property within the license granted hereunder, incorporate any other limitations, royalties or other provisions required by such third
party with respect to such sublicense, and address Symphony Evolution’s rights (if any) with respect to patent prosecution, maintenance and enforcement of patents and patent applications within such Third Party IP. 
  
 2.10. Separate Third Party License for Discontinued Program. In the
event of the expiration of a Discontinuation Option without exercise by Licensor, Symphony Evolution has the right to transfer to a third party, in accordance with Section 11.2(b) of the Amended and Restated Research and Development Agreement,
Symphony Evolution’s rights to the compounds and Products relating to the Program to which such Discontinuation Option pertained (the “Discontinued Program”). If Symphony Evolution identifies a third party that wishes to
obtain such rights, then upon Symphony Evolution’s request, (i) Licensor and Symphony shall amend this Agreement to terminate all of Symphony Evolution’s rights and obligations to the extent applicable to the Discontinued Program and (ii)
Licensor shall enter into a separate license agreement with such third party in which all of such terminated rights and obligations shall be conferred upon and undertaken by such third party. The terms and conditions of such license agreement shall
be identical to those contained herein, to the extent that such terms are applicable to the Discontinued Program and not dependent on any Operative Document other than this Agreement. Such terms shall include but not be limited to (1) provisions
allowing for termination of such license agreement upon a material, uncured breach of such license agreement by the third party on similar terms as provided herein with respect to 
  

 5 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Symphony Evolution and (2) a confidentiality provision that is not dependent on any of the Operative Documents.
Termination of this Agreement shall not effect such license agreement and Licensor’s obligation to enter into such a license agreement shall survive termination of this Agreement. 
  
 ARTICLE 3 
 SUBLICENSE TO CERTAIN THIRD PARTY INTELLECTUAL PROPERTY 
  
 3.1. General. The Parties acknowledge and agree that the license set forth in Section 2.2 does not include certain Intellectual Property (the “University IP”) which has been in-licensed
by Licensor from Yale University (“Yale”) pursuant to the Yale Exclusive License Agreement between Licensor and Yale effective January 9, 2002 (the “Yale Agreement”) and the Regents of the University
of California (“Regents”) pursuant to the Exclusive License and Bailment Agreement between Licensor and Regents effective July 25, 2001 (the “Regents Agreement” and together with the Yale Agreement,
the “University Agreements”). 
  
 3.2.
Option to Acquire Sublicense. In the event of (i) an expiration of a Discontinuation Option in respect of the Program relating to XL784 without exercise by Licensor or (ii) an expiration of the Purchase Option without exercise by Licensor
(and Licensor has not exercised a Discontinuation Option or Program Option in respect of the Program relating to XL784), then, upon Symphony Evolution’s written request, the Parties shall amend this Agreement to provide that, effective upon
such expiration of the Discontinuation Option or Purchase Option (as applicable), Symphony Evolution is granted a sublicense in and to such University IP to develop, make, have made, use, offer for sale, sell, and import XL784 and related Products;
provided, however, that, with respect to the Intellectual Property licensed under the Yale Agreement, Symphony Evolution’s sublicense shall be limited to Licensed Products as defined in the Yale Agreement, and, with respect to the
Intellectual Property licensed under the Regents Agreement, Symphony Evolution’s sublicense shall be limited to Licensed Products as defined in the Regents Agreement. The terms and conditions of the sublicense shall be consistent with and no
broader than the terms and conditions contained herein with respect to Licensed Intellectual Property; provided, however, such sublicense shall contain such additional terms and obligations as are required under the University
Agreements, including all terms set forth in Annex C. Without limiting Licensor’s obligations under Section 3.4, the option set forth in this Section 3.2 shall expire with respect to the Yale Agreement and the Regents Agreement upon the
expiration or termination of the Yale Agreement and the Regents Agreement, respectively. 
  
 3.3. Prosecution Fees. Symphony Evolution shall reimburse Licensor, within [ * ] after receipt of Licensor’s invoice, for [ * ] of the costs incurred by Licensor with respect to the filing,
prosecution and maintenance of all patent applications and patents included within the University IP. The foregoing obligation of Symphony Evolution shall terminate upon any exercise by Licensor of a Program Option or Discontinuation Option in
respect of the Program related to XL784. 
  
 3.4. Termination
or Amendment of University Agreements. Licensor may not (a) terminate any University Agreements or (b) amend any University Agreements in a 
  

 6 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 manner that would conflict with or otherwise limit Licensor’s obligations to Symphony Evolution under Section 3.2
without (i) giving Symphony Evolution reasonable advance written notice of such intention and (ii) in the event that Yale or Regents agree to (1) permit the Yale Agreement or the Regents Agreement, respectively, to be assigned to Symphony Evolution
or to (2) grant a substitute license to the relevant University IP to Symphony Evolution, executing any document necessary to effect such assignment or permit such substitute license and, in the event that Licensor terminates both the Yale Agreement
and the Regents Agreement, transferring to Symphony Evolution any applicable patent files in respect of the University IP (provided that the foregoing shall not be construed to require Licensor to pay any amounts or to undertake any additional
obligations). 
  
 3.5. No Conflicts. Licensor shall not
enter into any agreements with third parties that would conflict with or otherwise limit Licensor’s obligations to Symphony Evolution under Section 3.2. 
  
 ARTICLE 4 
 INTELLECTUAL
PROPERTY 
  
 4.1. Ownership. The Parties
acknowledge and agree that, as between Licensor and Symphony Evolution, Licensor or its licensors are the owner of all right, title and interest in and to the Licensed Intellectual Property, including without limitation Symphony Evolution
Enhancements. Symphony hereby assigns to Licensor all of Symphony Evolution’s rights and interests in any Symphony Evolution Enhancements. Symphony Evolution shall promptly disclose any Symphony Evolution Enhancement to Licensor, and shall use
reasonable efforts, at Licensor’s request and at no cost to Licensor, to cooperate fully with Licensor to transfer such Symphony Evolution Enhancements to Licensor. 
  
 4.2. Marking. Symphony Evolution shall mark, and shall cause all of its sublicensees to mark, all Products, or the
packaging thereof or materials related thereto, with the number of the applicable patents licensed hereunder in accordance with applicable U.S. patent law. 
  
 4.3. Prosecution and Maintenance. 
  
 (a) Unless otherwise set forth in this Section 4.3, (i) Licensor shall prepare, file, prosecute and maintain, in the name of Licensor, those patents and
patent applications in Licensed Patent Rights for which, as between Licensor and Third Party Licensors, Licensor has patent prosecution and maintenance rights at such time; and (ii) Licensor shall provide Symphony Evolution with (1) quarterly
reports regarding the status of the prosecution and maintenance of such patents and patent applications, (2) copies of any patent documents provided to GlaxoSmithKline with respect to such patents and patent applications, and (3) timely answers to
Symphony Evolution’s questions regarding the status of patents and patent applications in Licensed Patent Rights. 
  
 (b) Licensor will use commercially reasonable efforts to seek the allowance of broad generic claims, consistent with Licensor’s determination of
enforceability, business considerations and other factors. 
  

 7 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (c) Subject to any such costs paid by Third Party Licensors, the cost of such prosecution and maintenance
of Licensed Patent Rights shall be paid by Symphony Evolution. Upon the scope of any Licensed Patent Rights being amended so that the patent or patent application’s claims no longer relate to XL647, XL784, XL999 or any Products, such patent or
patent application shall cease to be a Licensed Patent Right and all rights and obligations with respect to such patent or patent application (including costs, fees, prosecution, maintenance and enforcement) shall revert to Licensor. 
  
 (d) Symphony Evolution shall not be responsible for the costs of any
interference or reexamination initiated by Licensor with respect to the Licensed Patent Rights (except to the extent allocated in the Development Budget), unless the Parties mutually agree in writing that it is reasonably necessary or useful to file
and prosecute such interference or re-examination in connection with such Licensed Patent Rights to protect their interests in such Licensed Patent Rights, which agreement will not be unreasonably withheld or delayed. In the event of such agreement,
unless otherwise agreed in writing by the Parties, Symphony Evolution shall pay all costs of such interference or reexamination. 
  
 (e) Each Party shall provide the prosecuting Party with reasonable cooperation under this Section 4.3. 
  
 (f) Symphony Evolution acknowledges that Licensor has certain obligations to
GlaxoSmithKline with respect to the prosecution and maintenance of certain patents and patent applications within the Licensed Patent Rights, including without limitation certain obligations to [ * ]. Nothing in this Agreement shall be
interpreted as requiring Licensor to breach such obligations to GlaxoSmithKline. Notwithstanding the foregoing, Licensor shall use commercially reasonable efforts to make, no later than upon any expiration of the Term without Licensor’s
exercise of the Purchase Option, any amendment to the GSK Agreement (as defined in Section 4.10) that may be necessary to provide that, upon any such expiration of the Term, GlaxoSmithKline shall no longer have any rights with respect to [ *
]. 
  
 4.4. Abandonment. The Parties acknowledge that
in the event Licensor desires to abandon any patent or patent application covering Licensed Patent Rights (whether during or after the Term), Licensor shall provide prompt, timely written notice thereof to Symphony Evolution. If Symphony Evolution
informs Licensor in writing at least [ * ] before the relevant deadline that Symphony Evolution desires to avoid such abandonment or lapse, then Licensor shall continue to prosecute or maintain such patent or patent application at Symphony
Evolution’s request and sole expense. Symphony Evolution understands and acknowledges that Licensor cannot allow certain patents or patent applications in the Licensed Patent Rights to lapse or become abandoned without [ * ]. Nothing in
this Section 4.4 shall be interpreted as giving Symphony Evolution rights that conflict with such Licensor obligations. 
  
 4.5. Infringement. Each Party agrees to immediately notify the other Party upon becoming aware of any infringement, misappropriation, illegal use
or misuse of the Licensed Intellectual Property and provide to the other party all available evidence of such infringement. 
  

 8 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 4.6. First Enforcement Right During Term. During the Term, as between the Parties, Licensor has
the first right, but not the obligation, to take action against others in the courts, administrative agencies or otherwise, at Symphony Evolution’s cost and expense, to prevent or terminate infringement, misappropriation, illegal use or misuse
of the Licensed Patent Rights or other Licensed Intellectual Property due to the manufacture, use or sale of a product or compound that might be competitive with a Product. Symphony Evolution shall, at its expense, cooperate with and reasonably
assist Licensor in any such action if so requested by Licensor, and, upon Licensor’s request, execute, file and deliver all documents and proof necessary for such purpose, including being named as a party to such litigation if requested by
Licensor or if required by law. Subject to Section 4.10, Symphony Evolution shall have the right to participate and be represented by its own counsel at its own expense in any such action, suit or proceeding with respect to Licensed Patent Rights
solely relating to Products for which Licensor has not exercised its Program Option or Discontinuation Option. Subject to Section 4.10, Licensor shall not enter into any settlement or compromise of such action, suit or proceeding that affects or
concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior written consent of Symphony Evolution, which consent shall not be unreasonably withheld or delayed.

  
 4.7. Post-Term Enforcement. 
  
 (a) Following the expiration of the Term without Licensor’s exercise of
the Purchase Option, as between the Parties, Symphony Evolution shall have the first right, but not the obligation, to take action against others in the courts, administrative agencies or otherwise, under Symphony Evolution’s direction and
control and at Symphony Evolution’s cost and expense, to prevent or terminate infringement, misappropriation, illegal use or misuse of any Licensed Patent Rights or other Licensed Intellectual Property that solely relate to a Product for which
Licensor has not exercised its Program Option or Discontinuation Option, due to the manufacture, use or sale of a product or compound that might be competitive with such Product. Licensor shall, at Symphony Evolution’s expense, cooperate and
reasonably assist Symphony Evolution in such action if so requested, and upon Symphony Evolution’s request, execute, file and deliver all documents and proof necessary for such purpose, including being named as a party to such litigation if
requested by Symphony Evolution or if required by law. Licensor shall have the right to participate and be represented in any such action, suit or proceeding by its own counsel at its own expense. Symphony Evolution shall not enter into any
settlement or compromise of such action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior written consent of Licensor,
which consent shall not be unreasonably withheld or delayed. 
  
 (b) Following the expiration of the Term without Licensor’s exercise of the Purchase Option, if Symphony Evolution does not take action under Section 4.7(a) within [ * ] of Licensor’s written request that Symphony Evolution
take such action, then Licensor shall have the option to commence any such action under its own direction and control, and at Licensor’s cost and expense. Symphony Evolution shall, at Licensor’s expense, cooperate and reasonably assist
Licensor in such action if so requested, and upon Licensor’s request, execute, file and deliver all documents and proof necessary for such purpose, including being named as a party to such litigation if requested by Licensor or if required by
law. Symphony Evolution shall have 
  

 9 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 the right to participate and be represented in any such action, suit or proceeding by its own counsel at its own expense.
Licensor shall not enter into any settlement or compromise of such action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior
written consent of Symphony Evolution, which consent shall not be unreasonably withheld or delayed. 
  
 4.8. Withdrawal of Enforcement. If either Party brings an action under this ARTICLE 4 and subsequently ceases to pursue or withdraws from such
action, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing party under the terms of this ARTICLE 4, provided that such substitution would not constitute a breach of Licensor’s obligations to
any Third Party Licensor. 
  
 4.9. Recoveries. All damages
or other compensation of any kind recovered in such action, suit, or proceeding or from any settlement or compromise brought under this ARTICLE 4 shall first be used to reimburse each Party for its expenses in connection with such action, suit or
proceeding, (in proportion to the expenses of each Party if recovery is insufficient to cover all such expenses) and the remainder of such recovery, after Licensor makes any other payments it is obligated to make to Third Party Licensors on account
of such recovery, shall be allocated [ * ]. 
  
 4.10.
Third Party Rights. Symphony Evolution acknowledges that Licensor has certain obligations to GlaxoSmithKline with respect to the enforcement of certain patents and patent applications within the Licensed Patent Rights, including without
limitation [ * ]. Nothing in this Agreement shall be interpreted as requiring Licensor to breach such obligations to GlaxoSmithKline. Notwithstanding the foregoing, (i) in the event that GlaxoSmithKline exercises its option to [ * ]
the Product Development and Commercialization Agreement between Licensor and GlaxoSmithKline dated October 28, 2002 (the “GSK Agreement”), Licensor shall use commercially reasonable efforts to amend the GSK Agreement as soon
as reasonably practical after such exercise but in no event later than any expiration of the Term without Licensor’s exercise of the Purchase Option, to provide that upon any expiration of the Term without Licensor’s exercise of the
Purchase Option, GlaxoSmithKline shall no longer have any right to [ * ]; and (ii) in the event GlaxoSmithKline does not exercise its option to [ * ], Licensor hereby represents and warrants to Symphony Evolution that upon expiration
of the Term pursuant to Section 1(c)(iii)(x) of the Purchase Option Agreement, GlaxoSmithKline shall no longer have any right to [ * ]. 
  
 ARTICLE 5 
 REPRESENTATIONS AND
WARRANTIES 
  
 5.1. Representations and Warranties of
Licensor. Licensor hereby represents and warrants to Symphony Evolution, that, as of the Effective Date: 
  
 (a) Licensor is the owner of all right, title, and interest in and to (i) all Licensed Patent Rights listed in Annex B and not identified as jointly owned
or licensed from a third party and (ii) the Regulatory Files; 
  

 10 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (b) Licensor has sufficient rights to grant the licenses granted hereunder and the grant of such licenses
does not and will not conflict with any agreement to which Licensor is a party or otherwise governing the Licensed Intellectual Property; 
  
 (c) To the Knowledge of Licensor, no third party is engaging in any activity that infringes or misappropriates the Licensed Intellectual Property;

  
 (d) No element of the Licensed Intellectual Property has been
adjudged invalid or unenforceable in whole or part, and to the Knowledge of Licensor, the issued patents within the Licensed Intellectual Property are valid and enforceable; 
  
 (e) To the Knowledge of Licensor, no actions or claims have been asserted, are pending or have been threatened, against
Licensor in writing alleging that the manufacture, use or sale of XL647, XL784 or XL999 misappropriates or infringes the intellectual property rights of any third party; and 
  
 (f) To the Knowledge of Licensor, the manufacture, use or sale of XL647, XL784 or XL999 by Symphony Evolution (or its
sublicensees) in strict accordance with the licenses herein and other terms of this Agreement will not misappropriate or infringe the intellectual property rights of any third party. 
  
 5.2. Disclaimer and Acknowledgement. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 5, THE LICENSED INTELLECTUAL
PROPERTY, PRODUCTS (AND THE COMPOUNDS THEREIN), TANGIBLE MATERIALS AND REGULATORY FILES ARE PROVIDED “AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, AND LICENSOR EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. LICENSOR DOES NOT WARRANT THE PERFORMANCE OF ANY PRODUCT (OR THE COMPOUND(S) THEREIN), INCLUDING THEIR SAFETY, EFFECTIVENESS OR
COMMERCIAL VIABILITY. ANY SYMPHONY EVOLUTION ENHANCEMENTS PROVIDED TO LICENSOR HEREUNDER ARE PROVIDED “AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND AND SYMPHONY EVOLUTION EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. 
  
 ARTICLE 6 
 INDEMNIFICATION AND LIMITATION OF LIABILITY 

 
 6.1. Indemnity. To the greatest extent permitted by applicable law,
Licensor shall indemnify and hold harmless Symphony Evolution, its Affiliates, and each of their respective officers, directors, employees, agents, members, managers, successors and assigns (each, a “Symphony Evolution Indemnified
Party”) and Symphony Evolution shall indemnify and hold harmless Licensor, its Affiliates and each of their respective officers, directors, employees, agents, members, successors and assigns (each, an “Exelixis Indemnified
Party” and together with Symphony Evolution Indemnified Party, the “Indemnified Parties”), from and 
  

 11 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 against any and all claims, losses, diminution in value, costs, interest, awards, judgments, penalties, fees (including
reasonable fees for attorneys and other professionals), court costs, liabilities, damages and expenses incurred by any Symphony Evolution Indemnified Party or Exelixis Indemnified Party (irrespective of whether any such Symphony Evolution
Indemnified Party or Exelixis Indemnified Party, as applicable, is a party to the action for which indemnification hereunder is sought), (collectively, a “Loss”) as a result of, arising out of, or relating to any and all
third party suits, claims, actions, proceedings, investigations, litigation or demands based upon: 
  
 (i) in the case of Licensor being the Indemnifying Party, (A) any breach of any representation or warranty made by Licensor herein or in
any certificate, instrument or document delivered hereunder, (B) any breach of any covenant, agreement or obligation of Licensor contained herein, or in any certificate, instrument or document delivered hereunder, or (C) any act of gross negligence
or willful misconduct by Licensor in performing its obligations under this Agreement; in each case, except (1) with respect to Losses for which Licensor is entitled to indemnification under this ARTICLE 6 or (2) to the extent such Loss arises from
the gross negligence or willful misconduct of a Symphony Evolution Indemnified Party, and 
  
 (ii) in the case of Symphony Evolution being the Indemnifying Party, (A) any breach of any representation or warranty made by Symphony
Evolution herein or in any certificate, instrument or document delivered hereunder, (B) any breach of any covenant, agreement or obligation of Symphony Evolution contained herein, or in any certificate, instrument or document delivered hereunder,
(C) any act of gross negligence or willful misconduct by Symphony Evolution in performing its obligations under this Agreement, or (D) the development, manufacture, use, handling, storage, sale or other disposition of the Product (other than those
Products arising from a Program for which Licensor exercised a Program Option or Discontinuation Option) after end of the Term; in each case, except (1) with respect to Losses for which Symphony Evolution is entitled to indemnification under this
ARTICLE 6 or (2) to the extent such Loss arises from the gross negligence or willful misconduct of an Exelixis Indemnified Party. 
  
 To the extent that the foregoing undertakings by Licensor and/or Symphony Evolution may be unenforceable for any reason, such Party shall make the maximum
contribution to the payment and satisfaction of any Loss that is permissible under applicable Law. 
  
 6.2. Notice of Claims. Any Indemnified Party that proposes to assert a right to be indemnified under this ARTICLE 6 shall notify Licensor or
Symphony Evolution, as applicable (the “Indemnifying Party”), promptly after receipt of notice of commencement of any action, suit or proceeding against such Indemnified Party (an “Indemnified
Proceeding”) in respect of which a claim is to be made under this ARTICLE 6, or the incurrence or realization of any Loss in respect of which a claim is to be made under this ARTICLE 6, of the commencement of such Indemnified Proceeding
or of such incurrence or realization, enclosing a copy of all relevant documents, including all papers served and claims made, but the omission so to notify the applicable Indemnifying Party promptly of any such Indemnified Proceeding or incurrence
or realization shall not relieve (a) such Indemnifying Party from any liability that it may have to such Indemnified Party under this ARTICLE 6 or otherwise, except, as to such 
  

 12 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Indemnifying Party’s liability under this ARTICLE 6, to the extent, but only to the extent, that such Indemnifying
Party shall have been prejudiced by such omission, or (b) any other indemnitor from liability that it may have to any Indemnified Party under the Operative Documents. 
  
 6.3. Defense of Proceedings. In case any Indemnified Proceeding shall be brought against any Indemnified Party, it
shall notify the applicable Indemnifying Party of the commencement thereof and such Indemnifying Party shall be entitled to participate in, and provided such Indemnified Proceeding involves a claim solely for money damages and does not seek an
injunction or other equitable relief against the Indemnified Party and is not a criminal or regulatory action, to assume the defense of, such Indemnified Proceeding with counsel reasonably satisfactory to such Indemnified Party, and after notice
from such Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election so to assume the defense thereof and the failure by such Indemnified Party to object to such counsel within [ * ] following its receipt of such
notice, such Indemnifying Party shall not be liable to such Indemnified Party for legal or other expenses related to such Indemnified Proceedings incurred after such notice of election to assume such defense except as provided below and except for
the reasonable costs of investigating, monitoring or cooperating in such defense subsequently incurred by such Indemnified Party reasonably necessary in connection with the defense thereof. Such Indemnified Party shall have the right to employ its
counsel in any such Indemnified Proceeding, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party unless: 
  
 (a) the employment of counsel by such Indemnified Party at the expense of the applicable Indemnifying Party has been authorized in writing by such
Indemnifying Party; 
  
 (b) such Indemnified Party shall have
reasonably concluded in its good faith (which conclusion shall be determinative unless a court determines that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between the applicable
Indemnifying Party and such Indemnified Party in the conduct of the defense of such Indemnified Proceeding or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes of action available to such
Indemnified Party (it being agreed that in any case referred to in this clause (b) such Indemnifying Party shall not have the right to direct the defense of such Indemnified Proceeding on behalf of the Indemnified Party); 
  
 (c) the applicable Indemnifying Party shall not have employed counsel
reasonably acceptable to the Indemnified Party, to assume the defense of such Indemnified Proceeding within a reasonable time after notice of the commencement thereof (provided, however, that this clause shall not be deemed to constitute a
waiver of any conflict of interest that may arise with respect to any such counsel); or 
  
 (d) any counsel employed by the applicable Indemnifying Party shall fail to timely commence or diligently conduct the defense of such Indemnified Proceeding; 
  
 in each of which cases the fees and expenses of counsel for such Indemnified
Party shall be at the expense of such Indemnifying Party. Only one counsel shall be retained by all Indemnified Parties with respect to any Indemnified Proceeding, unless counsel for any 
  

 13 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Indemnified Party reasonably concludes in good faith (which conclusion shall be determinative unless a court determines
that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between such Indemnified Party and one or more other Indemnified Parties in the conduct of the defense of such Indemnified Proceeding
or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes or action available to such Indemnified Party. 
  
 6.4. Settlement. Without the prior written consent of such Indemnified Party, such Indemnifying Party shall not settle or compromise, or consent to
the entry of any judgment in, any pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or related judgment (i) includes an unconditional release of such Indemnified Party from all liability for Losses arising out
of such claim, action, investigation, suit or other legal proceeding, (ii) provides for the payment of money damages as the sole relief for the claimant (whether at law or in equity), (iii) involves no finding or admission of any violation of law or
the rights of any Person by the Indemnified Party, and (iv) is not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified
Proceeding in respect of which any payment would result hereunder or under the Operative Documents without the prior written consent of the Indemnifying Party, such consent not to be unreasonably conditioned, withheld or delayed. 
  
 6.5. Limitation of Liability. TO THE GREATEST EXTENT PERMITTED BY
APPLICABLE LAW, NEITHER PARTY NOR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, MANAGERS, EMPLOYEES, INDEPENDENT CONTRACTORS OR AGENTS SHALL HAVE ANY LIABILITY OF ANY TYPE (INCLUDING, BUT NOT LIMITED TO, CLAIMS IN CONTRACT, NEGLIGENCE AND
TORT LIABILITY) FOR ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, THE LOSS OF OPPORTUNITY, LOSS OF USE OR LOSS OF REVENUE OR PROFIT IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR THE
SERVICES PERFORMED HEREUNDER, EVEN IF SUCH DAMAGES MAY HAVE BEEN FORESEEABLE. THE FOREGOING SHALL NOT LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO SECTION 6.1. 
  
 6.6. Insurance. Each Party shall maintain insurance, including on the part of Symphony Evolution, product liability
insurance, with respect to its activities under this Agreement. Such insurance shall be in such amounts and subject to such deductibles as are prevailing in the industry from time to time. Symphony Evolution shall maintain a minimum of an aggregate
of $10,000,000 in directors and officers insurance and an aggregate of $10,000,000 in product liability insurance. Notwithstanding anything to the contrary herein, this Section 6.6 shall survive only for a period of two (2) years following
termination or expiration of this Agreement. 
  

 14 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ARTICLE 7 
 TERM AND TERMINATION 
  
 7.1. Term. This Agreement shall commence on the Effective Date and shall remain in force until terminated as provided herein. 
  
 7.2. Termination. 
  
 (a) Either Party may terminate this Agreement at any time if the other Party is in material default or breach of this Agreement that has resulted in, or
would reasonably be expected to result in, a material adverse effect on the Programs or the non-breaching Party’s rights under the Operative Documents, and such material default or breach continues unremedied for a period of [ * ] after
written notice thereof is delivered to the defaulting or breaching party. 
  
 (b) Licensor may terminate this Agreement at any time upon written notice to Symphony Evolution if (i) Investors materially breaches Sections 2 or 3 of the Funding Agreement, (ii) Holdings breaches Section 2 of the
Subscription Agreement or (iii) Holdings or Symphony Evolution is in material default or breach the Purchase Option Agreement that has resulted in, or would reasonably be expected to result in, a material adverse effect on the Licensor’s rights
under the Operative Documents and such default or breach is not cured within [ * ] after written notice of such default or breach under the Purchase Option Agreement is delivered to the defaulting or breaching party. 
  
 (c) Licensor may terminate this Agreement in the event that the Amended and
Restated Research and Development Agreement is terminated by Licensor in accordance with the terms thereof due to a material breach or default by Symphony Evolution or Holdings (without limiting any rights to notice or cure that Symphony Evolution
or Holdings may have under such agreements). 
  
 (d) Upon any
termination of this Agreement, all license rights granted herein (except for those rights granted in or pursuant to Section 2.5) shall immediately terminate. 
  
 7.3. Survival. The following Sections and Articles shall survive any expiration or termination of this Agreement: Sections 2.10, 4.1, 5.2 and 7.3,
and Articles 6 and 8. 
  
 7.4. Bankruptcy. All rights and
licenses granted under this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Code”), licenses to “Intellectual Property” as defined in the
Code. The Parties agree that each Party shall retain and may fully exercise all of its rights and elections under the Code. 
  
 ARTICLE 8 
 MISCELLANEOUS

  
 8.1. Notices. Any notice, request, demand, waiver,
consent, approval or other communication which is required or permitted to be given to any Party shall be in writing and shall be deemed given only if delivered to the Party personally or sent to the Party by 
  

 15 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 facsimile transmission (promptly followed by a hard-copy delivered in accordance with this Section 8.1), by next Business
Day delivery by a nationally recognized courier service, or by registered or certified mail (return receipt requested), with postage and registration or certification fees thereon prepaid, addressed to the Party at its address set forth below:

  
 Licensor: 
  
 Exelixis, Inc. 
 170 Harbor Way 
 South San Francisco, CA 94083 
 Attention: Corporate Secretary 
 Facsimile: (650) 837-7951 
  
 Symphony Evolution: 
  
 Symphony Evolution, Inc. 
 7361 Calhoun Place, Suite 325 
 Rockville, MD 20850 
 Attn: Charles Finn 
 Facsimile: (301) 762-6154 
  
 with a copy
to: 
  
 Symphony Capital Partners, L.P.

 875 Third Avenue 
 18th Floor 
 New York, NY 10022 
 Attn: Mark Kessel 
 Facsimile: (212) 632-5401 
  
 or to such other address as such Party may
from time to time specify by notice given in the manner provided herein to each other Party entitled to receive notice hereunder. 
  
 8.2. Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or other attachments hereto) and the agreements referred to
herein (including the Operative Documents) constitute the entire agreement between the Parties with respect to the subject matter hereof, and no oral or written statement may be used to interpret or vary the meaning of the terms and conditions
hereof. This Agreement supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof, including the Original Agreement but excluding the Operative
Documents. 
  
 8.3. Assignment. Neither Party may assign or
otherwise transfer this Agreement without the prior written consent of the other Party; provided, however, that (i) Licensor may assign this Agreement or any of its rights and obligations hereunder without the consent of Symphony Evolution
(A) to an Affiliate or in connection with a merger or the sale of all or substantially all of the assets of the Licensor to which this Agreement relates, or (B) to the 
  

 16 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Surviving Entity in the event Licensor undergoes a Change of Control in compliance with Article 14 of the Amended and
Restated Research and Development Agreement, provided, however, the Licensed Patent Rights and Licensed Know-How shall not be construed, as a result of such assignment, to include any patent rights, know-how, trade secret, and other
intellectual property that, prior to such Change of Control, were owned or Controlled by the Person (other than Licensor) involved in such Change of Control; and (ii) after expiration of the Term without Licensor’s exercise of the Purchase
Option, Symphony Evolution may assign this Agreement to any Person without the prior, written consent of Licensor. Assignment of this Agreement by either Party shall not relieve the assignor of its obligations hereunder. This Agreement shall be
binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. 
  
 8.4. Headings. The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect in any way the
meaning or interpretation of the Agreement. 
  
 8.5.
Independent Contractor. Each Party shall be acting as an independent contractor in performing under this Agreement and shall not be considered or deemed to be an agent, employee, joint venturer or partner of the other Party. 
  
 8.6. Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any Party. 
  
 8.7. No Third-Party Beneficiaries. Except with respect to certain indemnification obligations and liability limitations pursuant to ARTICLE 6, nothing in this Agreement, either express or implied, is intended
to or shall confer upon any third party any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 
  
 8.8. Compliance with Laws. In performing under this Agreement, each Party shall comply with all applicable laws rules and regulations, including
without limitation, the United States Food and Drug Administration and the United States Export Administration Regulations. 
  
 8.9. Amendment. This Agreement may not be amended or modified except by an instrument in writing signed by authorized representatives of Licensor
and Symphony Evolution. 
  
 8.10. Governing Law; Consent to
Jurisdiction and Service of Process. 
  
 (a) This Agreement
shall be governed by, and construed in accordance with, the laws of the State of New York. 
  
 (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any New York State court or federal 
  

 17 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 court of the United States of America sitting in The City of New York, Borough of Manhattan, and any appellate court from
any jurisdiction thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in respect
of any such action or proceeding may be heard and determined in any such New York State court or, to the fullest extent permitted by law, in such federal court. Each of the Parties agrees that a final judgment in any such action or proceeding shall
be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that any Party may otherwise have to bring any action or proceeding relating to
this Agreement. 
  
 (c) Each of the Parties irrevocably and
unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any New York
State or federal court. Each of the Parties hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 
  
 8.11. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY
WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
  
 8.12. Counterparts. This Agreement may be executed in one or more counterparts, and by the respective Parties in
separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same Agreement. 
  
 8.13. No Waiver. The failure of either Party to enforce at any time for any period the provisions of or any rights
deriving from this Agreement shall not be construed to be a waiver of such provisions or rights or the right of such Party thereafter to enforce such provisions. 
  
 SIGNATURES FOLLOW ON NEXT PAGE 
  

 18 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first
written above by their respective duly authorized officers. 
  
  

	
	 SYMPHONY EVOLUTION, INC.

	
	 /s/ Harri V. Taranto

	 Name: Harri V. Taranto
 Title:   Chairman of the Board

  
  

			
	 SYMPHONY EVOLUTION HOLDINGS LLC
  

		
	 By:
	 	 Symphony Capital Partners, L.P.,

	 	 	 its Manager

		
	 By:
	 	 Symphony Capital GP, L.P.,

	 	 	 its general partner

		
	 By:
	 	 Symphony GP, LLC,

	 	 	 its general partner

  

	
	 /s/ Mark Kessel

	 Name: Mark Kessel

	 Title:   Managing Member

  
  

	
	 EXELIXIS, INC.

	
	             /s/ Christoph Pereira

	             Name: Christoph Pereira

	             Title:   Vice President, Legal Affairs and
Secretary

  

 19 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ANNEX A 
  
 DEFINITIONS 
  
 “$” means United States dollars. 
  
 “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as
amended. 
  
 “Act” means the Delaware
Limited Liability Company Act, 6 Del. C. § 18-101 et seq. 
  
 “Additional Funds” has the meaning set forth in Section 2(b) of the Funding Agreement. 
  
 “Additional Funding Date” has the meaning set forth in Section 3 of the Funding Agreement. 
  
 “Additional Party” has the meaning set forth in
Section 12 of the Confidentiality Agreement. 
  
 “Additional Regulatory Filings” means such Governmental Approvals as required to be made under any law applicable to the purchase of the Symphony Evolution Equity Securities under the Agreement. 
  
 “Ad Hoc Meeting” has the meaning set forth in
Paragraph 6 of Annex B to the Amended and Restated Research and Development Agreement. 
  
 “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Affected Member” has the meaning set forth in Section 27 of the Investors LLC Agreement.

  
 “Affiliate” means, with respect to any
Person (i) any Person directly or indirectly controlling, controlled by or under common control with such Person, (ii) any officer, director, general partner, member or trustee of such Person, or (iii) any Person who is an officer, director, general
partner, member or trustee of any Person described in clauses (i) or (ii) of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or “under common control with” shall mean the
possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person or entity, whether through the ownership of voting securities, by contract or otherwise, or the power to elect at least 50% of
the directors, managers, general partners, or persons exercising similar authority with respect to such Person or entities. 
  
 “Amended and Restated Research and Development Agreement” means the Amended and Restated Research and Development Agreement dated
as of June 9, 2005, among Exelixis, Holdings and Symphony Evolution. 
  

 A-1 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement. 
  
 “Auditors” means an
independent certified public accounting firm of recognized national standing. 
  
 “A Warrant Date” has the meaning set forth in Section 2.04 of the Warrant Purchase Agreement. 
  
 “A Warrants” has the meaning set forth in Section 2.01 of the Warrant Purchase Agreement. 
  
 “A Warrant Shares” has the meaning set forth in
Section 2.01 of the Warrant Purchase Agreement. 
  
 “Bankruptcy Code” means the United States Bankruptcy Code. 
  
 “Bloomberg” means Bloomberg L.P., a multimedia based distributor of information services, including data and analysis for financial markets and businesses. 
  
 “Bloomberg Screen” means the display page designated
on the Bloomberg service (or such other page as may replace that page on that service) for the purpose of displaying prices or bids of Exelixis Common Stock. 
  
 “Business Day” means any day other than Saturday, Sunday or any other day on which commercial banks in The City of New York or the
City of San Francisco are authorized or required by law to remain closed. 
  
 “B Warrants” has the meaning set forth in Section 2.02 of the Warrant Purchase Agreement. 
  
 “B Warrant Date” has the meaning set forth in Section 2.02 of the Warrant Purchase Agreement. 
  
 “B Warrant Shares” has the meaning set forth in
Section 2.05 of the Warrant Purchase Agreement. 
  
 “Capital Contributions” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Capitalized Leases” means all leases that have been or should be, in accordance with GAAP, recorded as capitalized leases.

  
 “Cash Available for Distribution” has
the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and Restated Research and Development Agreement. 
  

 A-2 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Change of Control” means and includes the occurrence of any of the following
events, but specifically excludes (i) acquisitions of capital stock directly from Exelixis for cash, whether in a public or private offering, (ii) sales of capital stock by stockholders of Exelixis, and (iii) acquisitions of capital stock by or from
any employee benefit plan or related trust: 
  
 (a) the merger, reorganization or consolidation of Exelixis into or with another corporation or legal entity in which Exelixis’ stockholders holding the right to vote with respect to matters generally immediately preceding such merger,
reorganization or consolidation, own less than fifty percent (50%) of the voting securities of the surviving entity; or 
  
 (b) the sale of all or substantially all of Exelixis’ assets or business. 
  
 “Class A Member” means a holder of a Class A
Membership Interest. 
  
 “Class A Membership
Interest” means a Class A Membership Interest in Holdings. 
  
 “Class B Member” means a holder of a Class B Membership Interest. 
  
 “Class B Membership Interest” means a Class B Membership Interest in Holdings. 
  
 “Class C Member” means a holder of a Class C
Membership Interest. 
  
 “Class C Membership
Interest” means a Class C Membership Interest in Holdings. 
  
 “Class D Member” means a holder of a Class D Membership Interest. 
  
 “Class D Membership Interest” means a Class D Membership Interest in Holdings. 
  
 “Clinical Budget” has the meaning set forth in
Section 4.1 of the Amended and Restated Research and Development Agreement. 
  
 “Clinical Plan” has the meaning set forth in Section 4.1 of the Amended and Restated Research and Development Agreement. 
  
 “Closing Date” means June 9, 2005. 
  
 “CMC” means the chemistry, manufacturing and controls documentation as required for filings with
Regulatory Authority relating to the manufacturing, production and testing of drug products. 
  
 “Code” means the Internal Revenue Code of 1986, as amended from time to time. 
  
 “Committed Capital” means $80,000,000.00. 
  
 “Common Stock” means the common stock, par value $0.01 per share, of Symphony Evolution. 

 

 A-3 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings LLC
Agreement. 
  
 “Company Property” has the
meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Confidential Information” has the meaning set forth in Section 2 of the Confidentiality Agreement. 
  
 “Confidentiality Agreement” means the Confidentiality Agreement, dated as of June 9, 2005, among Symphony Evolution, Holdings,
Exelixis, each Symphony Fund, SCP, SSP, Investors, Symphony Capital, RRD and Daniel F. Hoth, M.D., Herbert J. Conrad, and Alastair J.J. Wood, M.D. 
  
 “Conflict Transaction” has the meaning set forth in Article IX of the Symphony Evolution Charter. 
  
 “Control” means, with respect to any material,
information or intellectual property right, that a Party owns or has a license to such item or right, and has the ability to grant the other Party access, a license or a sublicense (as applicable) in or to such item or right as provided in the
Operative Documents without violating the terms of any agreement or other arrangement with any third party. 
  
 “C Warrants” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
  
 “C Warrant Date” has the meaning set forth in Section
2.06 of the Warrant Purchase Agreement. 
  
 “C Warrant
Shares” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
  
 “Debt” of any Person means, without duplication: 
  
 (a) all indebtedness of such Person for borrowed money, 
  
 (b) all obligations of such Person for the deferred purchase price of property or services (other than any portion of any
trade payable obligation that shall not have remained unpaid for 91 days or more from the later of (A) the original due date of such portion and (B) the customary payment date in the industry and relevant market for such portion), 
  
 (c) all obligations of such Person evidenced by bonds, notes, debentures or
other similar instruments, 
  
 (d) all obligations of such Person
created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person (whether or not the rights and remedies of the seller or lender under such agreement in an event of default are limited
to repossession or sale of such property), 
  
 (e) all
Capitalized Leases to which such Person is a party, 
  

 A-4 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 (f) all obligations, contingent or otherwise, of such Person under acceptance, letter of credit or
similar facilities, 
  
 (g) all obligations of such Person to
purchase, redeem, retire, defease or otherwise acquire for value any Equity Securities of such Person, 
  
 (h) the net amount of all financial obligations of such Person in respect of Hedge Agreements, 
  
 (i) the net amount of all other financial obligations of such Person under
any contract or other agreement to which such Person is a party, 
  
 (j) all Debt of other Persons of the type described in clauses (a) through (i) above guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed, directly or indirectly, by such Person through an agreement (A)
to pay or purchase such Debt or to advance or supply funds for the payment or purchase of such Debt, (B) to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling the debtor to
make payment of such Debt or to assure the holder of such Debt against loss, (C) to supply funds to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether such property is
received or such services are rendered) or (D) otherwise to assure a creditor against loss, and 
  
 (k) all Debt of the type described in clauses (a) through (i) above secured by (or for which the holder of such Debt has an existing right, contingent or
otherwise, to be secured by) any Encumbrance on property (including accounts and contract rights) owned or held or used under lease or license by such Person, even though such Person has not assumed or become liable for payment of such Debt.

  
 “Development Budget” means the budget
for the implementation of the Development Plan that is agreed upon by Exelixis and Symphony Evolution as of the Effective Date, as may be revised from time to time in accordance with the Development Committee Charter and the Amended and Restated
Research and Development Agreement. 
  
 “Development
Committee” has the meaning set forth in Article 3 of the Amended and Restated Research and Development Agreement. 
  
 “Development Committee Charter” has the meaning set forth in Article 3 of the Amended and Restated Research and Development
Agreement. 
  
 “Development Committee
Member” has the meaning set forth in Paragraph 1 of Annex B to the Amended and Restated Research and Development Agreement. 
  
 “Development Plan” means the development plan, covering all the Programs, agreed to by Exelixis and Symphony Evolution as of the
Effective Date, as may be revised from time to time in accordance with the Development Committee Charter and the Amended and Restated Research and Development Agreement. 
  
 “Directors” has the meaning set forth in the Preliminary Statement of the Indemnification Agreement.

  

 A-5 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Disclosing Party” has the meaning set forth in Section 3 of the Confidentiality
Agreement. 
  
 “Discontinuation Closing
Date” means the date of Symphony’s receipt of the Discontinuation Price. 
  
 “Discontinuation Option” has the meaning set forth in Section 11.2(a) of the Amended and Restated Research and Development Agreement. 
  
 “Discontinuation Price” has the meaning set forth in
Section 11.2(a) of the Amended and Restated Research and Development Agreement. 
  
 “Discontinued Program” has the meaning set forth in Section 2.10 of the Novated and Restated Technology License Agreement. 
  
 “Disinterested Directors” has the meaning set forth in Article IX of the Symphony Evolution Charter.

  
 “Distribution” has the meaning set
forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Effective Date” has the meaning set forth in the Novated and Restated Technology License Agreement. 
  
 “Effective Registration Date” has the meaning set forth in the Registration Rights Agreement 
  
 “Encumbrance” means (i) any security interest,
pledge, mortgage, lien (statutory or other), charge or option to purchase, lease or otherwise acquire any interest, (ii) any adverse claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement or other encumbrance of
any kind, preference or priority, or (iii) any other security agreement or preferential arrangement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement). 
  
 “Enhancements” means findings, improvements,
discoveries, inventions, additions, modifications, enhancements, derivative works, clinical development data, or changes to the Licensed Intellectual Property and Regulatory Files. 
  
 “Equity Securities” means, with respect to any Person, shares of capital stock of (or other
ownership or profit interests in) such Person, warrants, options or other rights for the purchase or other acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, securities convertible
into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or other acquisition from such Person of such shares (or such other interests), and other
ownership or profit interests in such Person (including, without limitation, partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are authorized or
otherwise existing on any date of determination. 
  

 A-6 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “ERISA” means the United States Employee Retirement Income Security Act of 1974,
as amended. 
  
 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
  
 “Exelixis” means Exelixis, Inc., a Delaware corporation. 
  
 “Exelixis Common Stock” means the common stock, par value $0.001 per share, of Exelixis. 

 
 “Exelixis Common Stock Valuation”
has the meaning set forth in Section 2(e) of the Purchase Option Agreement. 
  
 “Exelixis-GlaxoSmithKline Collaboration Committee” means the committee established by Exelixis and GlaxoSmithKline pursuant to Section 2.2 of the GSK Agreement. 
  
 “Exelixis Member” has the meaning set forth in
Section 2(c) of the Management Services Agreement. 
  
 “Exelixis Obligations” has the meaning set forth in Section 6.1 of the Amended and Restated Research and Development Agreement. 
  

“Exelixis Personnel” has the meaning set forth in Section 8.4 of the Amended and Restated Research and Development Agreement.

  
 “Existing NDA” has the meaning set
forth in Section 2 of the Confidentiality Agreement. 
  
 “Expert” has the meaning set forth in Section 11.2(c) of the Amended and Restated Research and Development Agreement. 
  
 “Extension Funding” has the meaning set forth in Section 2 of the Research Cost Sharing and Extension Agreement. 
  
 “External Directors” has the meaning set forth in the
preamble of the Confidentiality Agreement. 
  
 “FDA” means the United States Food and Drug Administration or its successor agency in the United States. 
  
 “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended and Restated Research and Development Agreement. 

 
 “Final Purchase Price” has the meaning set forth
in Section 2(j)(ii) of the Purchase Option Agreement. 
  
 “Financial Audits” has the meaning set forth in Section 6.7 of the Amended and Restated Research and Development Agreement. 
  

 A-7 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Financing” has the meaning set forth in the Preliminary Statement of the
Purchase Option Agreement. 
  
 “Fiscal
Year” has for each Operative Document in which it appears the meaning set forth in such Operative Document. 
  
 “Form S-3” means the Registration Form S-3 as defined under the Securities Act. 
  
 “FTE” has the meaning set forth in Section 4.1 of the
Amended and Restated Research and Development Agreement. 
  
 “Funded Capital” has the meaning set forth in Section 2.02(b) of the Warrant Purchase Agreement. 
  
 “Funding Agreement” means the Funding Agreement, dated June 9, 2005, among Exelixis, SCP and Investors. 
  
 “Funding Notice” has the meaning set forth in Section
2(a) of the Funding Agreement. 
  
 “Funds
Price” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “GAAP” means generally accepted accounting principles in effect in the United States of America from time to time. 
  
 “GlaxoSmithKline” means SmithKline Beecham
Corporation, a Pennsylvania corporation, doing business as GlaxoSmithKline. 
  
 “Governmental Approvals” means authorizations, consents, orders, declarations or approvals of, or filings with, or terminations or expirations of waiting periods imposed by any Governmental
Authority. 
  
 “Governmental Authority”
means any United States or non-United States federal, national, supranational, state, provincial, local, or similar government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or
arbitral body. 
  
 “Governmental Order”
means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
  
 “GSK Agreement” has the meaning set forth in Section 4.10 of the Novated and Restated Technology License Agreement. 
  
 “Hedge Agreement” means any interest rate swap, cap
or collar agreement, interest rate future or option contract, currency swap agreement, currency future or option contract or other similar hedging agreement. 
  

 A-8 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “HHMI” has the meaning set forth in Annex C of the Novated and Restated
Technology License Agreement. 
  
 “Holdings” means Symphony Evolution Holdings LLC, a Delaware limited liability company. 
  
 “Holdings Claims” has the meaning set forth in Section 5.01 of the Warrant Purchase Agreement. 
  
 “Holdings LLC Agreement” means the Second Amended and
Restated Limited Liability Company Agreement of Holdings dated June 9, 2005. 
  
 “HSR Act Filings” means the premerger notification and report forms required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
  
 “IND” means an Investigational New Drug Application,
as described in 21 U.S.C. § 355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof. 
  
 “Indemnification Agreement” means the Indemnification Agreement among Symphony Evolution and the
Directors named therein, dated June 9, 2005. 
  
 “Independent Accountant” has the meaning set forth in Section 2(i)(ii) of the Purchase Option Agreement. 
  
 “Initial Funds” has the meaning set forth in Section 2(a) of the Funding Agreement. 
  
 “Initial Holdings LLC Agreement” means the Agreement
of Limited Liability Company of Holdings, dated March 30, 2005. 
  
 “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of Investors, dated May 20, 2005. 
  
 “Initial LLC Member” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Interest Certificate” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
  
 “Interim Holdings LLC Agreement” means the Amended and Restated Agreement of Limited Liability Company of Holdings, dated June 2, 2005. 
  
 “Investment Company Act” means the Investment Company Act of 1940, as amended. 
  
 “Investment Overview” means the investment overview
describing the transactions entered into pursuant to the Operative Documents. 
  

 A-9 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Investment Policy” has the meaning set forth in Section 1(a)(viii) of the
Management Services Agreement. 
  
 “Investors” means Symphony Evolution Investors LLC. 
  
 “Investors LLC Agreement” means Amended and Restated Agreement of Limited Liability Company of Investors dated June 9, 2005. 
  
 “IRS” means the U.S. Internal Revenue Service. 
  
 “Knowledge” means the actual (and not imputed)
knowledge of the executive officers of Exelixis, without the duty of inquiry or investigation. 
  
 “Law” means any law, statute, treaty, constitution, regulation, rule, ordinance, order or Governmental Approval, or other governmental restriction, requirement or determination, of or by any
Governmental Authority. 
  
 “Ledger Fee”
has the meaning set forth in Section 6(b) of the Management Services Agreement. 
  
 “License” has the meaning set forth in the Preliminary Statement of the Purchase Option Agreement. 
  
 “Licensed Intellectual Property” means the Licensed Patent Rights, Symphony Evolution Enhancements, Licensor Enhancements and the
Licensed Know-How. 
  
 “Licensed Know-How”
means any and all proprietary technology (other than the University IP) that is [ * ] 
  
 “Licensed Patent Rights” means:[ * ] 
  
 “Licensor” means Exelixis. 
  
 “Licensor Enhancements” means [ * ] 
  
 “Lien” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Liquidating Event” has the meaning set forth in Section 8.01 of the Holdings LLC Agreement. 
  
 “LLC Agreements” means the Initial Holdings LLC
Agreement, the Interim Holdings LLC Agreement, the Holdings LLC Agreement, the Initial Investors LLC Agreement and the Investors LLC Agreement. 
  
 “Loss” has for each Operative Document in which it appears the meaning set forth in such Operative Document. 
  

 A-10 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Management Budget” has the meaning set forth in Section 4.1 of the Amended and
Restated Research and Development Agreement. 
  
 “Management Fee” has the meaning set forth in Section 6(a) of the Management Services Agreement. 
  
 “Management Plan” has the meaning set forth in Section 4.1 of the Amended and Restated Research and Development Agreement.

  
 “Management Services” has the meaning
set forth in Section 1(a) of the Management Services Agreement. 
  
 “Management Services Agreement” means the Management Services Agreement between Symphony Evolution and RRD, dated as of June 9, 2005. 
  
 “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth in such LLC
Agreement, and (ii) for each other Operative Document in which it appears, RRD. 
  
 “Manager Event” has the meaning set forth in Section 3.01(f) of the Holdings LLC Agreement. 
  
 “Material Adverse Effect” means, with respect to any Person, a material adverse effect on (i) the business, assets, property or
condition (financial or otherwise) of such Person or, (ii) its ability to comply with and satisfy its respective agreements and obligations under the Operative Documents or, (iii) the enforceability of the obligations of such Person of any of the
Operative Documents to which it is a party. 
  
 “Material Change” has the meaning set forth in Paragraph 12 of Annex B of the Amended and Restated Research and Development Agreement. 
  
 “Material Contract” has the meaning set forth in Section 3(j) of the Management Services Agreement.

  
 “Material Subsidiary” means, at any
time, a Subsidiary of Exelixis having assets in an amount equal to at least 5% of the amount of total consolidated assets of Exelixis and its Subsidiaries (determined as of the last day of the most recent fiscal quarter of Exelixis) or revenues or
net income in an amount equal to at least 5% of the amount of total consolidated revenues or net income of Exelixis and its Subsidiaries for the 12-month period ending on the last day of the most recent fiscal quarter of Exelixis. 
  
 “Maximum Committed Capital” has the meaning set forth
in Section 2.02(b) of the Warrant Purchase Agreement. 
  
 “Medical Discontinuation Event” means (a) as specified in each Protocol, those data that, if collected in such Protocol, demonstrate that such Protocol should not be continued or (b) a series of adverse events, side
effects or other undesirable outcomes that, when collected in a Protocol, would cause a reasonable FDA Sponsor to discontinue such Protocol. 
  

 A-11 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Membership Interest” means (i) for each LLC Agreement in which it appears, the
meaning set forth in such LLC Agreement, and (ii) for each other Operative Document in which it appears, the meaning set forth in the Holdings LLC Agreement. 
  
 “NASDAQ” means the National Association of Securities Dealers Automatic Quotation System. 
  
 “NDA” means a New Drug Application, as defined in the
regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof. 
  
 “Net Debt” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “Non-Exelixis Capital Transaction” means any (i) sale
or other disposition of all or part of the Symphony Evolution Shares or all or substantially all of the operating assets of Symphony Evolution, to a Person other than Exelixis or an Affiliate of Exelixis or (ii) distribution in kind of the Symphony
Evolution Shares following the expiration of the Purchase Option. 
  
 “Novated and Restated Technology License Agreement” means the Novated and Restated Technology License Agreement, dated as of June 9, 2005, among Exelixis, Symphony Evolution and Holdings. 
  
 “Operative Documents” means, collectively, the
Indemnification Agreement, the Holdings LLC Agreement, the Purchase Option Agreement, the Warrant Purchase Agreement, the Registration Rights Agreement, the Subscription Agreement, the Technology License Agreement, the Novated and Restated
Technology License Agreement, the Management Services Agreement, the Research and Development Agreement, the Amended and Restated Research and Development Agreement, the Research Cost Sharing and Extension Agreement, the Confidentiality Agreement,
the Funding Agreement and each other certificate and agreement executed in connection with any of the foregoing documents. 
  
 “Organizational Documents” means any certificates or articles of incorporation or formation, partnership agreements, trust
instruments, bylaws or other governing documents. 
  
 “Parties” means, for each Operative Document or other agreement in which it appears, the parties to such Operative Document or other agreement, as set forth therein (each a “Party”). With
respect to any agreement in which a provision is included therein by reference to a provision in another agreement, the term “Party” shall be read to refer to the parties to the document at hand, not the agreement that is referenced.

  
 “Payment Terms” has the meaning set
forth in Section 8.2 of the Amended and Restated Research and Development Agreement. 
  
 “Percentage” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Permitted Investments” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  

 A-12 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Permitted Investments Letter” means the Permitted Investments Letter dated as of
June 9, 2005, from Symphony Evolution to RRD, as set forth in Exhibit B to the Management Services Agreement. 
  
 “Permitted Lien” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Person” means any individual, partnership (whether
general or limited), limited liability company, corporation, trust, estate, association, nominee or other entity. 
  
 “Personnel” of a Party means such Party, its employees, subcontractors, consultants, representatives and agents. 
  
 “Prime Rate” means the quoted “Prime Rate”
at JPMorgan Chase Bank or, if such bank ceases to exist or is not quoting a base rate, prime rate reference rate or similar rate for United States dollar loans, such other major money center commercial bank in New York City selected by the Manager.

  
 “Product” means any product that
contains or comprises XL647, XL784 or XL999 or any Structurally Related Compound thereof. 
  
 “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Program Option” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development
Agreement. 
  
 “Program Option Closing
Date” has the meaning set forth in Section 11.1(d) of the Amended and Restated Research and Development Agreement. 
  
 “Program Option Exercise Date” has the meaning set forth in Section 11.1(b) of the Amended and Restated Research and
Development Agreement. 
  
 “Program
Option Exercise Notice” has the meaning set forth in Section 11.1(b) of the Amended and Restated Research and Development Agreement. 
  
 “Program Option Exercise Price” has the meaning set forth in Section 11.1(c) of the Amended and Restated Research and Development
Agreement. 
  
 “Program Option
Period” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
  
 “Programs” means those certain clinical programs pursuing indications for XL647, XL784, and XL999 in accordance with the
Development Plan (each a “Program”). 
  
 “Protocol” means a written protocol that meets the substantive requirements of Section 6 of the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective May 9, 1997 and is included within the
Clinical Plan or later modified or added to the Clinical Plan pursuant to Section 4.2 of the Amended and Restated Research and Development Agreement. 
  

 A-13 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Public Companies” has the meaning set forth in Section 5(e) of the Purchase
Option Agreement. 
  
 “Purchase Option”
has the meaning set forth in Section 1(a) of the Purchase Option Agreement. 
  
 “Purchase Option Agreement” means this Purchase Option Agreement dated as of June 9, 2005, among Exelixis, Holdings and Symphony Evolution. 
  
 “Purchase Option Closing Date” has the meaning set
forth in Section 2(a) of the Purchase Option Agreement. 
  
 “Purchase Option Dispute Notice” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
  
 “Purchase Option Exercise Notice” has the meaning set
forth in Section 2(a) of the Purchase Option Agreement. 
  
 “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the Purchase Option Agreement. 
  
 “Purchase Price” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “QA Audits” has the meaning set forth in Section 6.6
of the Amended and Restated Research and Development Agreement. 
  
 “Quarterly Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended and Restated Research and Development Agreement. 
  
 “Regents” has the meaning set forth in Section 3.1 of the Novated and Restated Technology License
Agreement. 
  
 “Regents Agreement” has the
meaning set forth in Section 3.1 of the Novated and Restated Technology License Agreement. 
  
 “Regents Claims” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  
 “Regents Indemnitees” has the meaning set forth in Annex C of the Novated and Restated Technology
License Agreement. 
  
 “Regents
Technology” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  

 A-14 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Registration Rights Agreement” means the Registration Rights Agreement dated as
of the Closing Date, between Exelixis and Holdings. 
  
 “Registration Statement” has the meaning set forth in Section 1(b) of the Registration Rights Agreement. 
  
 “Regulatory Authority” means the United States Food and Drug Administration, or any successor agency in the United States, or any
health regulatory authority(ies) in any other country that is a counterpart to the FDA and has responsibility for granting registrations or other regulatory approval for the marketing, manufacture, storage, sale or use of drugs in such other
country. 
  
 “Regulatory Allocation” has
the meaning set forth in Section 3.06 of the Holdings LLC Agreement. 
  
 “Regulatory Files” means any IND, NDA or any other filings filed with any Regulatory Authority with respect to XL647, XL784, XL999 or the Programs. 
  
 “Removed Director” has the meaning set forth in Section 3.01(h)(i) of the Holdings LLC Agreement.

  
 “Representative” of any Person means
such Person’s shareholders, principals, directors, officers, employees, members, managers and/or partners. 
  
 “Research and Development Agreement” means the Research and Development Agreement dated as of June 9, 2005, between Exelixis and
Holdings. 
  
 “Research Cost Sharing and Extension
Agreement” means the Research Cost Sharing and Extension Agreement dated as of June 9, 2005, between Exelixis, Holdings, and Symphony Evolution. 
  
 “RRD” means RRD International, LLC, a Delaware limited liability company. 
  
 “RRD Indemnified Party” has the meaning set forth in
Section 10(a)(i) of the Management Services Agreement. 
  
 “RRD Loss” has the meaning set forth in Section 10(a)(i) of the Management Services Agreement. 
  
 “Schedule K-1” has the meaning set forth in Section 9.02(a) of the Holdings LLC Agreement. 
  
 “Scientific Discontinuation Event” has the meaning
set forth in Section 4.2(f) of the Amended and Restated Research and Development Agreement. 
  
 “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership. 
  
 “SEC” means the United States Securities and Exchange Commission. 
  

 A-15 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Securities Act” means the Securities Act of 1933, as amended. 
  
 “Shareholder” means any Person who owns any
Symphony Evolution Shares. 
  
 “Solvent”
has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company. 
  
 “Stock Payment Date” has the meaning set forth in Section 2 of the Subscription Agreement. 
  
 “Stock Purchase Price” has the meaning set forth in
Section 2 of the Subscription Agreement. 
  
 “Structurally Related Compound” means: 
  
 (a) with respect to XL647, any compound that is [ * ] 
  
 (b) with respect to XL784, any compound that is [ * ] 
  
 (c) with respect to XL999, any compound that is [ * ] 
  
 “Subcontracting Agreement” has the meaning set forth
in Section 6.3 of the Amended and Restated Research and Development Agreement. 
  
 “Subcontractor” has the meaning set forth in Section 6.3 of the Amended and Restated Research and Development Agreement. 
  
 “Subscription Agreement” means the Subscription Agreement between Symphony Evolution and Holdings,
dated as of June 9, 2005. 
  
 “Subsidiary”
of any Person means any corporation, partnership, joint venture, limited liability company, trust or estate of which (or in which) more than 50% of (a) the issued and outstanding capital stock having ordinary voting power to elect a majority of the
board of directors of such corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation shall or might have voting power upon the occurrence of any contingency); (b) the interest in the capital or
profits of such partnership, joint venture or limited liability company; or (c) the beneficial interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more of its other
Subsidiaries or by one or more of such Person’s other Subsidiaries. 
  
 “Surviving Entity” means the surviving legal entity which is surviving entity to Exelixis after giving effect to a Change of Control. 
  
 “Symphony Capital” means Symphony Capital LLC, a
Delaware limited liability company. 
  
 “Symphony
Evolution” means Symphony Evolution, Inc., a Delaware corporation. 
  

 A-16 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Symphony Evolution Board” means the Symphony Evolution board of directors.

  
 “Symphony Evolution By-laws” means the
By-laws of Symphony Evolution, as adopted by resolution of the Symphony Evolution Board on June 9, 2005. 
  
 “Symphony Evolution Charter” means the Amended and Restated Certificate of Incorporation of Symphony Evolution, dated as of June
9, 2005. 
  
 “Symphony Evolution Director
Event” has the meaning set forth in Section 3.01(h)(i) of the Holdings LLC Agreement. 
  
 “Symphony Evolution Enhancements” means [ * ] 
  
 “Symphony Evolution Equity Securities” means the Common Stock and any other stock or shares issued by Symphony Evolution.

  
 “Symphony Evolution Loss” has the
meaning set forth in Section 10(b) of the Management Services Agreement. 
  
 “Symphony Evolution Securities Encumbrance” has the meaning set forth in Section 4(b)(ii) of the Purchase Option Agreement. 
  
 “Symphony Evolution Shares” has the meaning set forth in Section 2.02 of the Holdings LLC Agreement.

  
 “Symphony Funds” means Symphony
Capital Partners, L.P., a Delaware limited partnership, and Symphony Strategic Partners, LLC, a Delaware limited liability company (each a “Symphony Fund”). 
  
 “Symphony Member” has the meaning set forth in Section 4.2(d) of the Amended and Restated Research
and Development Agreement. 
  
 “Tangible
Materials” means [ * ]. 
  
 “Tax
Amount” has the meaning set forth in Section 4.02 of the Holdings LLC Agreement. 
  
 “Technology License Agreement” means the Technology License Agreement, dated as of June 9, 2005, between Exelixis and Holdings. 
  
 “Term” means the period starting on the Closing Date and ending upon the termination or expiration
of the Purchase Option Period. 
  
 “Territory” means the world. 
  
 “Third Party IP” has the meaning set forth in Section 2.9 of the Novated and Restated Technology License Agreement. 
  

 A-17 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Third Party Licensor” means (a) a third party from which Exelixis has received a
license or sublicense to Licensed Intellectual Property or (b) a third party to which Exelixis has granted a license or sublicense to the Licensed Intellectual Property. As of the Closing Date, GlaxoSmithKline is the only Third Party Licensor.

  
 “Transfer” has for each Operative
Document in which it appears the meaning set forth in such Operative Document. 
  
 “Transferee” has, for each Operative Document in which it appears, the meaning set forth in such Operative Document. 
  
 “University Agreements” has the meaning set forth in Section 3.1 of the Novated and Restated
Technology License Agreement. 
  
 “University
IP” has the meaning set forth in Section 3.1 of the Novated and Restated Technology License Agreement. 
  
 “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Warrant Closing” has the meaning set forth in
Section 2.07 of the Warrant Purchase Agreement. 
  
 “Warrant Date” has the meaning set forth in Section 2.06 of the Warrant Purchase Agreement. 
  
 “Warrant Purchase Agreement” means the Warrant Purchase Agreement dated as of the Closing Date, between Exelixis and Holdings.

  
 “Warrants” has the meaning set forth
in Section 2.03 of the Warrant Purchase Agreement. 
  
 “Warrant Share Legend” has the meaning set forth in Section 6.02 of the Warrant Purchase Agreement. 
  
 “Warrant Shares” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
  
 “XL647” means: [ * ] 
  
 “XL784” means: [ * ] 
  
 “XL999” means: [ * ] 
  
 “Yale” has the meaning set forth in Section 3.1 of
the Novated and Restated Technology License Agreement. 
  

 A-18 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 “Yale Agreement” has the meaning set forth in Section 3.1 of the Novated and
Restated Technology License Agreement. 
  
 “Yale
Claims” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  
 “Yale Indemnitees” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  
 “Yale Technology” has the meaning set forth in Annex
C of the Novated and Restated Technology License Agreement. 
  

 A-19 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ANNEX B 
  
 PATENTS INCLUDED IN LICENSED PATENT RIGHTS 
  
 [ * ] 
  

 B-1 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 ANNEX C 
  
 SUBLICENSE TERMS 
  
 [ * ] 
  

 C-1 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]